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ABSTRACT

Regulator of G protein signaling protein 2 (RGS2) attenuates G Protein-Coupled Receptor
(GPCR) signaling by promoting the hydrolysis of GTP in the activated Gα subunit to GDP,
thereby governing many physiological and pathophysiological signals. However, how RGS2
itself is regulated remains to be elucidated. In this study, our principal goal was to discover the
molecular mechanisms controlling RGS2 degradation and if altered degradation affects Gα
signaling. RGS2 has four initiation sites (at residues 1, 5, 16, and 33), resulting in the existence
of four distinct N-terminal initiation site variants. Additionally, there are naturally occurring
mutations in this region at residues 5 (RGS2 M5V), 14 (RGS2 R14I), 18 (RGS2 K18N) and
23 (RGS2 G23D), which may be associated with a phenotypic profile seen in individuals with
the mutant forms. Here we report that the use of each initiator methionine residue, as well as
mutations within the N-terminus of RGS2, can have profound effects on RGS2 half-life.
Additionally, we show a correlation between RGS2 half-life and the ability to attenuate Gαq/11
signaling. Finally, we provide evidence that RGS2 is degraded via the ubiquitin-proteasome
pathway. Considering the importance of RGS2 in pathophysiological conditions, altered
degradation associated with initiation variants or mutant isoforms could be contributing to such
conditions.
Key Words
G protein-coupled receptors (GPCR), Regulator of G protein signaling proteins 2 (RGS2),
GTPase accelerating proteins (GAPs), protein degradation, single nucleotide polymorphisms
(SNPs), cell signaling.
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Chapter 1: Introduction
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1

INTRODUCTION

1.1

G PROTEIN SIGNALING

1.1.1

G PROTEIN SIGNALING OVERVIEW

G Protein-Coupled Receptors (GPCRs) are seven transmembrane domain-spanning proteins
that constitute one of the largest receptor classes within the human body1. The human genome
is reported to contain greater than 720 GPCRs2. GPCRs have numerous physiological and
pathological roles due to the transduction of extracellular signals into intracellular effector
pathways through receptor activation1. Receptor activation may occur from a broad range of
ligands including proteins, peptides, and organic compounds1. Upon activation, GPCRs turn
on heterotrimeric G proteins by promoting the binding of the activating nucleotide GTP in
exchange for GDP on the G protein’s Gα subunit1. The Gα subunit, along with the bound GTP,
is thought to dissociate from the Gβγ dimer, with both complexes subsequently able to
modulate the activities of a variety of effectors3. Gα signaling is dependent on which Gα family
(i.e., Gαs, Gαq/11, Gαi/o, Gα12/13) is activated (Table 1.1). Gαs activates, while Gαi/o inhibits,
receptor-dependent adenylyl cyclase function, leading respectively to an increase or decrease
in the second messenger cyclic adenosine monophosphate (cAMP)3. The Gαq/11 G protein
family couple receptors to phospholipase Cβ (PLC-β) to increase the levels of the second
messengers inositol (1,4,5)-trisphosphate (IP3) and diacylglycerol (DAG), subsequently
leading to an increase in cytosolic calcium (Ca2+) and the activation of protein kinase C (PKC)3.
The Gα12/13 G protein family members activate RhoGTPase nucleotide exchange factors
(RhoGEFs) which in turn activate a small monomeric GTPase, RhoA, and other downstream
effectors2. These GPCR-mediated signaling pathways are involved in many human diseases,
and are thus the focus of approximately 30-40% of today’s commercially available drugs4.
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Table 1.1. Classes of Gα subunits, their expression pattern, and their effectors
Members of the Gα family, their expression patterns, and their signaling functions
Gαs

Gαs

Ubiquitous
Stimulation of adenylyl cyclase

Gαi/o

Gαolf

Olfactory neurons

Gαi1/2/3

Ubiquitous

GαoA/B

Brain

Closes Ca2+ channels

Gαot1/2

Retina

Stimulation of cGMP-phosphodiesterase

Gαz

Brain/platelets

Inhibition of adenylyl cyclase

Inhibition of adenylyl cyclase

K+ channel closure
Gαq/11

Gαq/11

Ubiquitous

Gα15/16

Hematopoietic cells

Gα14

Lung, kidney, liver

Gα12/13 Gα12/13

Ubiquitous

Stimulation of PLC-β
Activate RhoGEFs
Activate RhoGEFs
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G protein activation is terminated by the intrinsic GTPase activity of the Gα subunit, which
hydrolyzes the GTP back to GDP, resulting in the reformation of the inactive Gαβγ
heterotrimer (Figure 1.1). After activation, GPCRs may undergo receptor internalization, and
many are able to signal from endosomal compartments, primarily via G protein-independent
mechanisms5. This process appears to be regulated by phosphorylation by GPCR Kinases
(GRKs) and arrestin binding5,6. There are diverse mechanisms within a cell that regulate the
magnitude and duration of G protein signaling. Nucleotide exchange can be modulated by
Guanine nucleotide Exchange Factors (GEFs) and Guanine nucleotide Dissociation Inhibitors
(GDIs), whereas the GTPase activity of the Gα subunit may be enhanced by GTPase
Accelerating Proteins (GAPs)7 (Figure 1.2). One family of GAPs are the Regulator of G
protein Signaling (RGS) proteins, which promote the hydrolysis of GTP on the activated Gα
subunit to GDP, thereby curtailing GPCR signaling8. The RGS protein family, including RGSlike proteins, contain more than 30 members, of which most act as GAPs by binding to and
deactivating Gα proteins9. The majority of RGS proteins act upon Gαi/o, with a subset acting
upon Gαq/1110. One protein, RGS2, however, is unique in that it preferentially acts upon Gαq/11
over Gαi/o, while maintaining the ability to impede adenylyl cyclase activity to obstruct
signaling via Gαs. The mechanism resulting in the inhibition of Gαs signaling by RGS2 remains
controversial. It has been suggested to be caused by the binding of Gαs and RGS2, but also the
binding of certain isoforms of adenylyl cyclase with RGS211. The fundamental role of RGS2
has been extensively researched as it is important to understand how such an abundant receptor
class such as GPCRs are regulated. However, it is unknown how RGS2 itself is regulated. In
the following study, we used an RGS2 overexpression model as a tool to study how RGS2 is
regulated, specifically the rate of degradation of RGS2, and how this could contribute to Gα
signaling.
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Fig 1.1. Receptor-mediated activation of G proteins. The binding of an extracellular ligand
to the GPCR causes a conformational change in the receptor, which leads to the activation of
the Gα subunit. This activation promotes the exchange of GDP for the activating nucleotide
GTP and is thought to cause the dissociation of the Gβγ dimer from the complex. Both the
GTP-bound Gα and free Gβγ are capable of initiating downstream signals by interacting with
effectors. This process is terminated by the intrinsic GTPase activity of the Gα subunit which
can hydrolyze the GTP back to GDP, forming the inactive Gαβγ heterotrimer complex.
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Fig 1.2 Regulation of G protein signaling. The rate of nucleotide exchange can be altered by
guanine nucleotide dissociation inhibitors (GDIs) such as RGS12 and guanine nucleotide
exchange factors (GEFs) such as GPCRs. GTP hydrolysis can be regulated by GTPase
accelerating proteins (GAPs) such as RGS proteins.
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1.1.2

Gαq/11 SIGNALING

Upon ligand binding, GPCRs have the ability to activate G proteins by promoting the exchange
of a GDP nucleotide for the activating GTP nucleotide on the Gα subunit of the G protein3.
Intracellular signaling is dependent upon which G protein family is activated. Gαq/11 signaling
begins when the enzyme PLC-β is activated by the G protein3. PLC-β catalyzes the hydrolysis
of the phospholipid phosphatidylinositol 4,5-bisphosphate (PIP2) into two secondary
messengers: IP3 and DAG12. IP3 diffuses throughout the cytosol and binds to IP3 receptors
located on the endoplasmic reticulum (ER) or the sarcoplasmic reticulum (SR) in order to
release calcium (Ca2+)13. Due to the higher Ca2+ concentration within the ER compared to the
cytosol, activation of IP3 receptors causes a rapid rise in cytosolic Ca2+ levels12.
One role of Ca2+ and DAG is to promote the activation of some isoforms of the enzyme protein
kinase C (PKC)12. PKC has a major role in regulating many cellular functions including
transcription of certain genes, regulating many membrane receptors and ion channels,
regulating many cellular phosphorylation cascades12, cytoskeleton remodelling, and cellular
survival signals14. Ca2+ has other intracellular functions, including binding to and activating
the intermediate messenger calmodulin (CaM)15,16. CaM mediates many cellular processes
such as inflammation, metabolism, apoptosis, smooth muscle contraction, memory, and
immune response15. CaM is able to activate a protein phosphatase, calcineurin (CaN), by
binding to a regulatory domain within CaN, causing a conformational change and resulting in
activation of the phosphatase17. CaN can trigger the activation of the transcription factor
Nuclear Factor of Activated by T-cells (NFAT)18. NFAT can regulate gene transcription
including the upregulation of hypertrophic response genes, which may lead to cardiac
hypertrophy18. Gαq/11 can also signal in a PLC-β-independent manner. The Rho GTPase family

8

belongs to the Ras superfamily and have a role in many cellular processes such as secretion,
smooth muscle contraction, migration, neurite retraction, and gene transcription19. Rho
proteins cycle between inactive GDP-bound and an active GTP-bound state, and this activation
is catalyzed by GEFs (i.e., RhoGEFs)19. It is well known that Gα12/13 G proteins activate
RhoGEFs. It has only been recently shown that p63RhoGEF links specifically Gαq/11-coupled
receptors to RhoA by a direct interaction with GTP-liganded Gαq/11 proteins19. This discovery
provides another avenue for Gαq/11 to signal through, adding to the complexity of G protein
signaling. Clearly, the Gαq/11 signaling pathway followed can depend on many factors such as
which Gαq/11-coupled GPCR is activated.
1.1.3 Gαs SIGNALING
Gαs signaling begins the same way as Gαq/11 signaling – ligand binding causes a conformational
change in the GPCR, allowing for the activation of the G protein. Gαs signaling is mediated by
the activation of adenylyl cyclase from the Gαs-GTP complex20. Adenylyl cyclase catalyzes
the cyclization of 5’-Adenosine Triphosphate (ATP) to the second messenger cyclic adenosine
monophosphate (cAMP)21. cAMP is an important second messenger that can activate several
different signaling proteins including the enzyme Protein Kinase A (PKA, or cAMP-dependent
protein kinase)22. PKA is a tetramer composed of two catalytic domains and two regulatory
domains. When present, the regulatory subunits bind cAMP and release the catalytic domains
which can phosphorylate target proteins22. PKA has several cellular functions including
regulation of glycogen, sugar, and lipid metabolism23, sequestering Rac to control cytoskeleton
remodeling24, activating the reward system25, vasodilation26 and renin secretion27. PKA is wellknown for regulating transcription by phosphorylating various transcription factors including
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cAMP-response element-binding protein (CREB), cAMP-responsive element modulator
(CREM), and activating transcription factor 1 (ATF1)28.

An important downstream effector in the cAMP-dependent pathway is Exchange Protein
directly Activated by cAMP (EPAC). EPAC is a Guanine nucleotide Exchange Factor (GEF)
that promotes the activation of small GTPases, such as Rap1, whose major function is to
increase cell adhesion via integrin receptors28,29. Another cAMP-dependent function is to bind
to and modulate a family of cyclic-nucleotide-gated ion channels that conduct calcium28. The
Gαs pathway can be quite variable and has many pathways to choose from. It is thought that
complex molecular mechanisms must be occurring to allow cross-talk between the pathways.
This cross talk will allow the pathways to agonize or antagonize each other to ultimately get
the desired response of the specific receptor-bound ligand29.
1.1.4 STRUCTURAL BASIS OF Gα ACTIVATION
All Gα proteins are composed of two domains: a GTPase domain and a helical domain30. The
GTPase domain contains three flexible loops that undergo substantial structural changes during
nucleotide exchange and the hydrolysis cycle31. The GTPase domain hydrolyses GTP and also
contains binding sites for Gβγ, receptors, and effectors30. The helical domain of the Gα subunit
is composed of a six α-helix bundle that forms a cap over the nucleotide-binding site in order
to bury the bound nucleotide within the protein30,31. The helical domain is unique to each of
the heterotrimeric G proteins suggesting it may regulate coupling of specific G proteins and
other regulators32.

Although GPCR-stimulated GDP release is not fully understood, several mechanisms have
been proposed30. One model suggests that upon GPCR activation, the receptor uses the N-
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terminal helix of Gα as a lever arm to pull Gβγ away from Gα, resulting in GDP release30. A
second model suggests that the receptor uses the N-terminal helix of Gα to force Gβγ into Gα,
allowing Gγ to engage the helical domain of Gα, resulting in GDP release30. Independent of
either model, the higher cellular GTP concentration relative to GDP means that GTP will more
likely bind to the transient nucleotide-free state of Gα30, causing Gα protein activation. In
addition, the binding of GTP to Gα can be facilitated and stabilized by magnesium (Mg2+),
which has been suggested to act as a keystone locking the Gα in a conformation that favours
dissociation from Gβγ and effector binding33. The intrinsic GTP hydrolysis varies among
different Gα proteins34, however, the relatively slow GTPase activity of Gα subunits (other
than Gαs) can be enhanced by GAPs.

1.2 REGULATOR OF G PROTEIN SIGNALING (RGS) PROTEINS
The duration of G protein signaling is determined by the length of time that the Gα subunit is
in the GTP-bound or activated state35. GTP hydrolysis was originally thought to be an
unregulated function of Gα subunit that provides intrinsic control over the activation period of
a G protein35. However, there remained an inconsistency between the rapid G protein signal
inactivation rates in vivo and relatively slow GTP hydrolysis rate in vitro36,37. This suggested
there is a mechanism in vivo regulating the intrinsic GTPase activity of Gα that could accelerate
the process. One family of proteins that are known to serve such a role are Regulators of G
protein Signaling (RGS) proteins.

SST2, Egl-10, G0S8 (later renamed RGS2), and GAIP (RGS19) were among the first RGS
proteins identified in the mid 1990s38,39,40,41. Since the 1990s, more than 30 RGS proteins,
including RGS-like proteins, have been discovered and added to the RGS family9,42. All RGS
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proteins share an RGS domain of approximately 120 amino acids which mediates the GAP
activity of the RGS protein. There are four subfamilies based on their sequence similarity in
the RGS domain: A/RZ, B/R4, C/R7, and D/R12 (Figure 1.3). Although many RGS proteins
are relatively simple proteins, containing little more than an RGS domain, some RGS proteins
contain additional functional domains other than the RGS domain. Thus, RGS protein may
have non-canonical functions distinct from deactivating Gα subunits43.

1.2.1 RGS PROTEIN-G PROTEIN BINDING
RGS proteins have the ability to bind to the active state of Gα proteins and increase the rate of
GTP hydrolysis upwards of 2000 fold45. The molecular and structural mechanism of RGS
proteins GAP activity has been extensively studied. The classical RGS domain consists of 9 αhelices bundled into two lobes. One lobe is formed by helices αI, αII, αIII, αVIII, and αIX
whereas the other lobe consists of the αIV, αV, αVI, and αVII helices46,47. The RGS domain
has been shown to be crucial in the G protein-RGS protein interface by both NMR and
crystallography, and this interaction is important to mediate a RGS protein’s GAP activity46,48.
It is likely that the interaction between the αVII and αVIII helices of RGS domain and the Gα
helical domain is what allows for selectivity between different RGS protein and G proteins47,49.

1.2.2 MECHANISMS OF RGS PROTEIN GAP ACTIVITY
The mechanism of RGS protein GAP activity was first studied using RGS4-Gαi1 as a
model46,50. It was concluded that RGS4 stimulates GTP hydrolysis primarily by binding to and
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Fig. 1.3. Structures and classification of mammalian RGS proteins. RGS proteins are
classified into subfamilies based on the alignment of RGS domain amino acid sequences.
Proteins are oriented with their N termini on the left and their C termini on the right.
Abbreviations: RGS: Regulator of G protein signaling; DEP: Dishevelled, worm EGL-10, and
mammalian Pleckstrin; R7H: R7 binding proteins; GGL: G game like; PDZ: PSD95, Dgl and
ZO-1/2; PTB: protein tyrosine binding; RID:

Ras interaction domain. Colours: Blue:

Amphipathic helix; Green: GoLoco motif; Yellow: Coiled coil domain. Adapted from
Hollinger and Hepler, 2002, with permission44.
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creating an environment that favours the transition state conformation of the Gα subunit which
is most likely to hydrolyse GTP50. The crystal structure of RGS4 bound to the transition state
of Gαi1 (i.e., with GDP and AlF4- in the binding pocket, mimicking the conformation of the
GTP-activated form that precedes GTP hydrolysis) provided supplementary information about
the interaction between RGS protein and G protein. It was shown that RGS4 does not directly
interact with either GDP or AlF4-51. Instead, RGS4 catalyzes GTP hydrolysis by reducing the
energy of the transition state of the Gα subunit and destabilizing the Gα-GTP complex46.
Additional studies using other RGS-Gα complexes such as RGS16/Gαt and RGS9/Gαt52,53,
p115-RhoGEF/Gα13/i154, RGS1/ Gαi/o, and RGS19/Gαi/o55, each confirmed that the RGS
domains bind to and stabilize the flexible regions of Gα during the transition state of GTP
hydrolysis.

1.2.3 SELECTIVE REGULATION BY RGS PROTEINS

The selectivity of RGS proteins is dependent on the amino acid residue sequence elements
within the RGS domain, as well as the helical domain of the Gα protein39. The vast majority
of RGS proteins are selective for the Gαi/o and Gαq subfamilies of G proteins, but their affinity
toward different G proteins varies somewhat within these two subfamilies. For example, RGS4
is known to interact strongly with both Gαi/o and Gαq56 but RGS19 interacts strongly with Gαi1,
Gαi3, and Gαo, while maintaining the ability to weakly bind Gαi2 but not appearing to bind with
Gαs or Gαq at all57. The available crystal data suggests that RGS19 has a serine at the position
corresponding to the asparagine position in RGS4, which may contribute to the difference in
G protein selectivity46,58. Recently, studies have identified many other RGS proteins can also
regulate Gαq/11 signaling functions, although not block Gαq/11 signaling by accelerating GαGTPase activity59. For example, GRK2 contains an RGS domain that binds tightly to Gαq to
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block its interactions with PLC-β without affecting Gαq/11-GTPase activity59. Thus, the effector
antagonism of RGS proteins can be more complex than simply the binding to G proteins.

The N-terminal regions of RGS proteins serve as important determinants for their biochemical
selectivity. Each of the subfamilies of RGS proteins contain N-terminal regions with diverse
structural features. The R4/B subfamily each have an amphipathic α-helix of about 30 aminoacid residues with multiple palmitoylation sites60. The RZ/A subfamily have a cysteine-rich
domain referred to as a cysteine string motif61. In other RGS subfamilies, molecular domains
such as the DEP domain (R7/C subfamily) or PDZ domain (R12/D) are near the N-terminus
of the protein. The N-terminus of RGS proteins regulates selectivity by either mediating RGS
protein sub-cellular localization or making direct contact with specific GPCRs or effector
proteins62. For example, deletion of the N-terminus of RGS2 greatly reduces its plasma
membrane and nuclear localization63.

Though all RGS proteins share a similar RGS domain, there are very different tissue expression
patterns among different RGS proteins. For example, RGS2 is ubiquitously expressed
throughout all cells, suggesting a more general function39. On the other hand, RGS9-1 is solely
expressed in the retina, while its splice variant RGS9-2 is expressed in certain regions of the
brain64,65. Other examples include RGS5 being highly expressed in the vascular tissue with
lower expression in skeletal muscle and kidney tissue66 and RGS21 expression in taste bud
cells67. The relatively specific tissue distribution of RGS proteins suggests that there may be
specialized roles of each RGS protein.
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1.2.4 NON-CANONICAL FUNCTIONS OF RGS PROTEINS

RGS proteins contain other molecular domains outside of the conserved RGS domain that have
binding partners other than Gα subunits of G proteins and thus function to regulate either their
subcellular localization, GAP activity, or receptor coupling. These additional domains may
enable RGS proteins to serve non-canonical functions and limit signaling via GAPindependent mechanisms such as effector antagonism and GDI43. RGS proteins can also bind
many different effector proteins such as adenylyl cyclases, PLC-β, and G protein-coupled
inwardly-rectifying potassium (GIRK) channels42. In some cases, RGS proteins can bind to
effectors and interfere with the productive interaction between these two proteins, thus, RGS
proteins function as effector antagonists68. On the other hand, RGS proteins may also serve as
anchors and create RGS-G protein-effector complexes, resulting in rapid transduction and
temporal focusing of the G protein signal9.

Regulation of non-G protein signaling by RGS proteins has also been investigated. Both
RGS13 and RGS16 have been found to interact with the p85α subunit of phosphatidylinositol
3-kinase (PI3 kinase) in a G protein-independent manner, and thus inhibit signaling events
downstream of PI3 kinase69,70. RGS3 has been shown to interact with the Smad family of
proteins to interfere to TGF-β-induced dimerization of Smad3 and Smad4, thereby inhibiting
Smad-mediated gene transcription71. Other RGS or RGS-like proteins have been suggested to
play a role in regulating nuclear signaling, for example, by modulating gene transcription 43.
Work done by our lab has identified a novel inhibitory role of RGS2 on global protein
synthesis, wherein RGS2 interacts with the ε subunit of eIF2B to inhibit its GEF activity on
eIF272.
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1.2.5 PATHOPHYSIOLOGICAL FUNCTIONS OF RGS PROTEINS

Characterizing the specific roles of RGS proteins in the context of whole-organism
homeostasis and pathophysiology has been a major concerted effort in the field and knockout
mouse strains have been essential to these discoveries73. Knockout animals have shed light on
the importance of RGS proteins in many physiological conditions. RGS1-deficient mice
showed abnormal responses to chemokines and improper maturation of germinal centers74,
whereas RGS13-deficient mice showed a different immune system phenotype which resulted
in increased mast-cell degranulation and anaphylaxis69. RGS2-deficient mice have a
completely different immune issue in that their B cell quantities and differentiation are normal,
however, they are unable to mount a robust T cell immune response73. RGS2 is ubiquitously
expressed throughout all cells types which is presumably why RGS2-deficient mice exhibit
many abnormal phenotypes. Besides immune issues, RGS2-deficient mice also show increased
anxiety and decreased male agression75, decreased fat stores76, and constitutive hypertension
due to a decreased inhibitory influence on Gαq/11-mediated vasoconstriction77–79.

Other RGS-deficient mice also show dysregulation in the cardiovascular system. Mice
deficient in RGS5, which is mainly found in vascular smooth muscle and pericytes, exhibit
constitutive hypotension73. Mice deficient in RGS4, a RGS protein with high expression in the
sinoatrial node of the heart, experience exaggerated decreases in heart rate when the
parasympathetic nervous system is activated73. Finally, RGS6-deficient mice have a mild
resting bradycardia and altered heart rate responses to pharmacological agents73.

Alterations in RGS pathways have been implicated in several disease states, especially
cancer80. Prostate cancer, head and neck squamous cell carcinoma, breast cancer, and lung
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cancer all demonstrate variable risk with alterations in the RGS pathway80. There is increasing
evidence that point mutations or Single Nucleotide Polymorphisms (SNPs) within RGS genes
may predispose individuals to disease states associated with RGS protein pathways. For
example, SNPs located on the RGS4 gene have been associated with bladder cancer80 and also
with schizophrenia81. RGS SNPs have also been linked to several other human diseases
including celiac disease82, anxiety and panic disorders83, platelet hypofunction84, and
hypertension85,86. Extensive research has not been performed on these SNPs, as most have just
been identified as potential contributors to physiological disease states. Both genome-wide
association studies and molecular mechanistic studies need to be performed in order to confirm
the role RGS SNPs play in disease development.

1.2.6 RGS PROTEINS AS POTENTIAL DRUG TARGETS

GPCRs and their linked signaling pathways are the direct targets for a vast majority of currently
used pharmaceuticals87,88. RGS proteins have a unique ability to modulate G protein signaling
combined with highly regionalized localization, for example, within the nervous system 87.
Developing small molecules that can inhibit RGS protein/Gα binding have been proposed as
molecular targets to potentiate the actions of endogenous neurotransmitters in a multitude of
disease states such as Alzheimer’s disease, depression, and epilepsy89. Also, targeting RGS
proteins has been proposed to boost efficacy of current GPCR-directed drugs while decreasing
the therapeutic dose in order minimize adverse side effects89. Targeting RGS proteins have
also been proposed to decrease tolerance and possibly reduce desensitization to agonist drugs.
For example, opioid tolerance depends on GRK-mediated phosphorylation of agonist-bound
receptor and binding of arrestin. RGS inhibitors should also reduce desensitization and
tolerance by reducing the fractional receptor occupancy that is required for an analgesic
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effect89. Currently, these are proposed outcomes of RGS protein drug targeting. If the
physiological and pathophysiological roles of RGS proteins are well-established, then targeting
RGS proteins could become a viable pharmacological approach in animal studies and human
diseases.

1.2.7 OVERVIEW OF RGS2

The R4/B subfamily of RGS proteins contain ten members including, RGS1-5, RGS8, RGS13,
RGS16, RGS18, and RGS21. The R4/B subfamily contain the smallest RGS proteins,
containing relatively short peptide sequences (2-80 amino acids) flanking the N- and Cterminal ends of the RGS domain, with just one exception (RGS3)90. RGS3 exists as several
isoforms that are all splice variants from the RGS3 gene. The shortest splice variant contains
little more than the RGS domain, synonymous with the other R4/B subfamily, whereas the
longer isoforms may contain PDZ, PEST, and/or acidic domains90. PDZ domains are proteinprotein interaction domains that are specialized for binding to short peptide motifs at the
extreme carboxy termini of other proteins, although they can have other modes of action91. A
PEST domain is rich in proline (P), glutamic acid (E), serine (S), and threonine (T), which is
associated with proteins that have a short intracellular half-life92.

RGS2, the focus of this thesis, is unique among the RGS protein family. RGS2 is a 211 amino
acid protein that contains an ~120 amino acid conserved RGS domain between residues 80205 that mediates it GAP activity93. RGS2 also contains four initiator methionine residues at
positions 1, 5, 16, and 33, any of which can initiate protein production in mammals94 (Figure
1.4). RGS2 is found ubiquitously throughout the body72,95–100, which allows it to play an
important role in many physiological processes. Indeed, RGS2 appears to play an important
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Fig 1.4. Representative RGS2 protein with the first 40 amino acids. The RGS domain is
located between amino acids 80 and 205. Alternate start sites (initiation variants) are
highlighted in red. Point substitutions are highlighted in blue.
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role in pathophysiological conditions such as hypertension101–103, anxiety104, aggression75, and
oxidative stress105. RGS2 is upregulated by Gαs- and Gαq/11-mediated signals, which appear to
cause cross-desensitization between the pathways106. RGS2 is also upregulated by factors such
as heat-shock105, electrical stimulation107, ischemia108, and other cellular stress inducing
agents. Interestingly, other stress related proteins (such as ATF4) are upregulated by cellular
stress and also contain multiple initiation sites, similar to that of RGS2. Hence, RGS2 may
have multiple sites of initiation in order to synthesize important isoforms of the protein during
stressful cellular conditions.
While RGS4, another R4/B subfamily member, possesses good GAP activity for Gαi/o and
Gαq/11, RGS2 lacks in vitro GAP activity for Gαi/o, but has been reported to be quite potent in
blocking Gαq/11-directed activation of PLC-β93. The structural basis for RGS2’s poor GAP
activity for Gαi/o compared to RGS4 is thought to be due to a three amino acid substitutions in
the Gα binding surface of RGS293,109. It is suggested that these structural differences in RGS2
may impair the binding of RGS2 to Gαi/o but in theory could favour the binding to Gαq/1193. An
important factor in the binding of RGS2 to Gα proteins is plasma membrane targeting.
Truncation of the first 78 amino acids (N-terminus) of RGS2 results in the loss of effector
antagonism of RGS2 but not its GAP activity, suggesting that the N-terminus may have a
plasma membrane targeting function93,110.
RGS2 also has the ability to inhibit Gαs pathways. The structural basis for its inhibitory effects
remains unknown and controversial as to whether RGS2 binds Gαs, isoforms of adenylyl
cyclase, or both. When purified recombinant RGS2 was added to purified recombinant
adenylyl cyclase V cytoplasmic domains, it was able to decrease cAMP production stimulated
by either Gαs or by forskolin111. However, others have demonstrated that RGS2 protein can be
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immunoprecipitated with purified Gαs112. Additionally, RGS2 is recruited to the plasma
membrane when co-expressed with Gαs and when RGS2 is co-expressed with isoforms of
adenylyl cyclase11. Regardless of how RGS2 inhibits Gαs, this function of RGS2 is important
in many physiological processes including the olfactory system. Addition of recombinant
RGS2 to olfactory epithelia membranes blocked odorant-induced cAMP production
suggesting that RGS2 negatively regulates Gαs-mediated pathways, as Gαolf belongs to the
Gαs-family93.

RGS2 is interesting in that it can have numerous SNPs, several of which can affect its
regulation and function84,86 (Figure 1.4). One point mutation, RGS2 M5V, is found within a
Japanese population of hypertensive patients, but it was not identified in healthy control
patients86. Another point mutation, RGS2 G23D, has been associated with a phenotypic patient
profile that includes borderline IQ, hirsutism, upregulation of bone alkaline phosphatase due
to an increase in bone mass, and decreased platelet Gαs function leading to enlarged, round
platelets with abnormal α-granules84. The authors concluded that the genetic defect in RGS2
causes a preference for translation via the first two initiator methionine residues at amino acid
positions 1 and 5, rather than 16 and 33, to initiate protein production.

Within the larger two forms of RGS2 is a putative adenylyl cyclase binding domain (amino
acids 9-11), which is absent in the two shorter forms of RGS284. Therefore, if the altered
genetic sequence of RGS2 G23D is causing a shift towards production of the longer forms of
RGS2, Gαs signaling may be inhibited more strongly, resulting in the pathological conditions
seen in patients84. The mechanism as to how these pathophysiological conditions occur remains
controversial as it is still unclear if RGS2 in fact directly binds to all forms of adenylyl
cyclase11.
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Mice lacking RGS2 have previously been shown to spontaneously develop hypertension and
cardiac hypertrophy and this correlates with decreased attenuation of Gαq/11 signaling113.
Authors concluded that it could also be due to altered kidney function114 and increased
circulating catecholamines115. This has led us to hypothesize RGS2 M5V may not be attenuate
Gαq/11 signaling as well as wild-type RGS2, thus potentially leading to hypertension86. By
looking at the phenotypic profile of a RGS2 G23D patient, it was shown that there is a
decreased platelet Gαs function, suggesting that this mutant will attenuate Gαs-linked GPCR
signaling to a greater degree than wild-type RGS2 protein. There are two RGS2 SNPs without
any known pathophysiological effects but are found in between the RGS2 M5V and RGS2
G23D mutations; RGS2 R14I and RGS2 K18N. Although there is little known about these
mutations, RGS2 R14I is close to, but is not part of the putative adenylyl cyclase binding region
at amino acids 9-11. RGS2 K18N also contains a SNP between the RGS2 M5V and RGS2
G23D SNPs, and appears to not play a role in hypertension85. Currently, it is unknown if and
how the mutations affect Gα signaling, but we hypothesize that these RGS2 SNPs may affect
the stability of the protein, thus influencing Gα signal attenuation.

1.3 KINETIC REGULATION OF G PROTEIN ACTIVITY

To understand how G protein-mediated signaling occurs, the kinetics of G protein activation
and deactivation must first be understood. The first step in the G protein activation/deactivation
cycle is GDP dissociation. The relatively high concentration of GTP in a cell (while free GDP
is relatively low) leads to a rapid association of GTP after GDP dissociation30. Thus, the rate
of nucleotide exchange depends highly on the rate of GDP dissociation. GTP dissociation is
relatively slow and as a result, GTP is normally hydrolyzed by the G protein even before it
dissociates30. Overall, nucleotide exchange and GTP hydrolysis are two key reactions that
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determine the duration of G protein signaling30. As alluded to in section 1.1.1, the kinetics of
G protein signaling are tightly regulated by GEFs, GDIs, and GAPs, and the delicate balance
among these regulatory mechanisms can affect the rate and magnitude of G protein signaling.

1.3.1 GEF-MEDIATED ACTIVATION OF G PROTEINS

From a kinetic point of view, the fractional activation of the G protein reflects the balance
between GEF-promoted activation and GAP promoted deactivation116. GEFs, such as GPCRs,
dramatically increase the rate of GDP dissociation, resulting in an increase in GTP association
and ultimately, G protein activation.

An interesting non-receptor G protein activator is Ric-8 (resistance to inhibitors of
cholinesterase 8A), which shares similar but not identical mechanism with that of the GPCR.
Ric-8 favours binding with high affinity to the open conformation of the G protein thus, the
effect of Ric-8 on fractional activation of G protein may be nucleotide concentration
dependent116. Ric-8 also promotes the dissociation of both GDP and GTP which, at lower
concentrations of GTP (< 500 nM), helps to reduce GTP turnover116. At higher GTP
concentrations, as are found intracellularly (~150 μM), GTP association is greater than
dissociation and the Gα-GTP form predominates116. Ric-8 has also been reported to increase
cellular G protein levels by stabilizing G proteins in a nucleotide-free conformation thus
preventing denaturation117. This finding has profound implications with respect to Gαq/11
activation kinetics as Gαq/11 tends to have a fast denaturation rate when in the nucleotide-free
state118. As the binding of GTP competes with the denaturation of ligand-free Gαq/11, increasing
the concentration of GTP decreases denaturation and thus enables the formation of Gαq/11-GTP.
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The fact that Ric-8 is able to decrease the denaturation rate of the G protein will further benefit
the formation of the active GTP-bound G protein.

1.3.2 GDI-MEDIATED INHIBITION OF G PROTEIN ACTIVATION

Nucleotide exchange is intrinsically limited by the relatively slow rate of nucleotide
dissociation. GDI activity, which decreases the GDP dissociation, may also lead to an overall
reduction in G protein activation. Among the GDIs identified for heterotrimeric G proteins, the
best studied proteins are those containing the GoLoco motif (also called GPR domain and
GPSM domain) – a highly conserved 19 amino acid motif119 that has a much higher binding
affinity for GDP-bound Gα relative to either nucleotide-free or GTP-bound Gα120. It has been
shown that the rate of GTPγS binding, which reflects nucleotide exchange, is decreased up to
80% in the presence of GoLoco proteins or peptide derived from the GoLoco motifs of RGS12
and RGS14121,122. The function of GoLoco motifs becomes more complicated by its propensity
to compete with Gβγ in binding to Gα. The Gβγ dimer is also able to slow down the rate of
intrinsic GDP dissociation from the Gα subunit up to 50 fold, depending on the specific G
protein in question123. Notwithstanding this, Gβγ is necessary for receptor-stimulated Gα
activation since it can stabilize Gα-receptor coupling.

1.3.3 GAP-MEDIATED GTP HYDROLYSIS

The GTP hydrolysis rate of proteins can be increased up to 2000 fold by GAPs such as RGS
proteins124. As a result, RGS proteins negatively regulate the G protein cycle by both
dampening signaling output and by rapidly terminating G protein activation upon removal of
a stimulus124. Interestingly, kinetic characterization indicated that the rate of the overall steadystate GTPase reaction measured in the presence of PLC-β is 10 times faster than the rate of
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GTP binding to G protein in the absence of PLC-β125. Moreover, even though the GTP
hydrolysis is dramatically increased by GAPs, the fact that the fractional activation of G protein
still remains high suggests that either the activation rate is also increased or the GAP activity
is inhibited while the receptor is activated.

One theory that supports the idea that RGS proteins are able to potentiate receptor-mediated G
protein activation is a proposed kinetic scaffolding mechanism125,126. In this model, GAPs are
able to reduce depletion of local Gα-GDP levels to permit rapid recoupling to receptor and
sustained G protein activation. In combination with the kinetic scaffolding mechanism, there
is another model based on the idea of physical scaffolds. This model suggests that RGS proteins
may directly or indirectly interact with the receptor and facilitate receptor-G protein coupling
and promote signal onset thus, RGS proteins may act as a scaffold to assemble different
signaling components127. The theories described provide insights into how G protein signaling
is regulated by different factors. It is prudent to understand how the mechanisms are regulated
themselves, whether it be due to transcriptional differences in the mechanisms or alterations in
protein levels.

1.4 PROTEIN DEGRADATION

The half-life of a protein depends on how rapidly it is produced and degraded. The majority of
proteins are degraded in a selective protein ubiquitin-proteasomal fashion which depends on
three classes of enzymes; E1, E2, and E3128. E1 enzymes attach an ATP to ubiquitin, E2
enzymes are ubiquitin-conjugating enzymes, and E3 are ubiquitin-ligase enzymes bind E2
enzymes and the target protein to mediate ubiquitination; this cycle repeats itself until the
ubiquitinated proteins are recognized and the protein is ultimately degraded by the
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proteasome128. Selective protein turnover results in protein levels that can rapidly change in
response to external stimuli that alter degradation rates. Furthermore, abnormal products, such
as misfolded proteins, can be rapidly degraded128. Long lived proteins typically are degraded
by the lysosomal pathway, which is a non-selective pathway129. It is often assumed that
lysosomal degradation is only for degrading endocytosed particles, but endogenous proteins
also have the ability to bind to the lysosomal membrane, which controls the rate of entry into
the lysosome and subsequent degradation of the protein129. This process is relatively slow
compared to the rapid ubiquitin-proteasome pathway, which is why it is thought that only long
lived proteins are degraded via the lysosomal pathway129. RGS proteins, specifically RGS4
and RGS5, have previously been shown to be degraded by the ubiquitin-proteasome pathway,
and their rapid degradation was attributed to the presence of specific amino acids within their
N-termini130,131.

1.4.1 N-END RULE PATHWAY

In 1986, Alexander Varshavsky and co-workers developed the N-end rule which proposes that
the N-terminal amino acid of a protein determines its half-life or likelihood of being
degraded132 (Figure 1.5). Specific amino acids within the N-termini, called N-degrons, present
degradation signals that may promote the rapid breakdown of proteins131,133. The idea behind
the N-end rule is that degrons on short-lived proteins in eukaryotes are recognized by ubiquitin
ligases, which mediate the conjugation of ubiquitin to an internal lysine residue of the substrate,
resulting in the ATP-dependent degradation by the 26S proteasome128,130,133,134.
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Fig. 1.5. The classical N end rule pathway. Tertiary destabilizing residues asparagine and
glutamine are, respectively, deamidated into secondary destabilizing residues aspartic acid and
glutamic acid by NTAN NtN-amidase and NTAQ NtQ-amidase, which are in turn arginylated
by ATE1-encoded arginyl (R)-transferase isoforms generating the degron arginine. N terminal
cysteine is converted to a substrate of arginylation through its oxidation. N terminal arginine,
as well as type 1 and type 2 residues, are recognized and bound by the N-recognin family
members, which mediate ubiquitylation and proteasomal degradation, via detection by the
UBR box. Adapted from Tasaki et al., 2012, with permission134.
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1.4.2 RECOGNITION OF N-DEGRONS

The recognition of N-degrons is mediated by N-recognins which induce protein ubiquitylation
and proteolysis via the proteasome. The mechanism of substrate selectivity was revealed by
the discovery that the UBR box, conserved in many N-recognins, is the substrate recognition
domain135,136. The mammalian genome encodes seven known UBR box proteins, UBR1UBR7, which all contain signature substrate recognition components of the ubiquitinproteasome system, with exception of UBR4134. UBR1-UBR3 are referred to as canonical due
to their sequence homology, size (~200 kDa), and conserved domains including the UBR box
(type 1 binding site), N domain (type 2 binding site), RING finger (ubiquitinylation domain),
and autoinhibitory domain (which sterically blocks the UBR box and N domain)134. UBR4UBR7 are referred to as non-canonical UBR box proteins as they are non-sequelogous to one
another134.
The recognition of N-end rule substrates initiates with hydrogen bonding with the free α-amino
group of the N-terminal residue134. Once engaged, N-recognin establishes a substrate-selective
interaction through hydrogen bonds with the positively charged side chains. Overall, N-end
rule interactions are largely confined to the first two residues, enabling N-recognins to select
substrates on the basis of destabilizing N-terminal residues137,138. UBR1 and UBR2 also have
a second substrate-binding domain, the N domain, which binds to type 2 degrons (Figure
1.5)139.

1.4.3 UBIQUITIN ACTIVATION AND CONJUGATION
Ubiquitin can be activated by two ubiquitin-activating enzymes (E1), UBA1 and UBA6140.
UBA1 is the major E1 ubiquitin-activating enzyme responsible for the bulk of ubiquitin
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conjugation to E2 enzymes, whereas UBA6 is an alternate E1 enzyme with a designated E2
enzyme, USE1140. Though UBA1 is used more often, it has been shown that mice lacking
UBA6 die in utero, suggesting that UBA6 plays an essential role in mammalian
development141. Recently, it has been shown that UBA6 mediates the ubiquitin activation and
conjugation for the canonical N-recognins, UBR1-UBR3, and one substrate of UBA6activated N-recognins includes RGS4142. Once ubiquitin has been activated by E1 enzymes,
the ubiquitin molecule is transferred to a member of the ubiquitin-conjugating enzymes (E2).
This transfer forms a thioester-charged E2 intermediate that can associate with an E3 ubiquitinligase enzyme to promote ubiquitin transfer from the E2 to the substrate of interest and
ultimately lead to degradation142.

1.4.4 RGS PROTEINS AND THE N END RULE

Although all proteins are not intrinsically unstable, they may become so via N-arginylation or
the substitution of an amino acid for a destabilizing arginine residue130. RGS4 and RGS5 are
two proteins known to undergo N-arginylation and ultimately follow the ubiquitin-proteasome
degradation pathway131. Both RGS4 and RGS5 have a conserved N-terminal
cysteine at amino acid position 2130, and cysteine is known to undergo N-arginylation131. After
mutating the N-terminal cysteine of RGS4 and RGS5 to a serine, these proteins were no longer
found to be rapidly degraded, suggesting that rapid degradation of RGS4 and RGS5 was reliant
on the conserved cysteine130. An N terminal cysteine is rapidly oxidized after the removal of
the initiator methionine (by a methionine aminopeptidase), which results in a pre-N-degron
protein, allowing arginylation to occur by ATE1-encoded Arg-transferase131. An N-terminal
arginine allows E3 enzymes (ubiquitin-protein ligase E3 component n-recognin 1 and 2, or
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UBR1 and UBR2) to recognize the amino acid, and thus ubiquitin can be added to the protein.
Further additions of ubiquitin ultimately result in degradation of the protein143. The
physiological importance of protein arginylation has been established by the discovery that
ATE1-deficient mouse embryos die due to cardiac and vascular development abnormalities134.

The rapid ubiquitin-proteasome degradation caused by the conserved cysteine residues of
RGS4 and RGS5 has also been reported to occur when there is a conserved glutamine or
asparagine residue at amino acid position 2131. The mechanism to generate N-degrons from a
glutamine or asparagine differs from that involving a conserved cysteine. Instead of oxidation,
glutamine and asparagine residues undergo deamidation134. Deamidation is a chemical reaction
in which an amide functional group is removed or replaced. N-terminal glutamine and
asparagine are respectively deamidated by NTAQ1-encoded NtQ-amidase and NTAN1encoded NtN-amidase, which are not analogous to each other134. The physiological function of
deamidation was initially identified in NTAN1-deficient mice who were found to exhibit
impaired memory, learning, and social behaviour which appeared to be primarily due to
dysregulation of proteasomal degradation of the microtubule-associated protein 2 in the
hippocampal neurons134. Glutamine and asparagine are respectively deamidated into the
secondary destabilizing residues glutamic acid and aspartic acid, which are in turn arginylated
by ATE1-encoded arginyl (R)-transferase isoforms generating the degron arginine and
continuing on with degradation of the protein134. Although this process has not been reported
in RGS2, which has a conserved glutamine at amino acid position 2, it is plausible that RGS2
protein may also be rapidly ubiquitinated and degraded in a similar fashion to RGS4 and RGS5.
There is evidence that RGS2 is rapidly ubiquitinated and degraded. When HEK293 cells were
transiently transfected with RGS2 and HA-ubiquitin, they were shown to co-
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immunoprecipitate together and to a greater extent in the presence of the proteasome inhibitor
MG132144. Also, since mutations in the N-terminal domains of RGS4 and RGS5 lead to altered
degradation rates130, it is possible that RGS2 SNPs may also have altered degradation rates
compared to the wild-type RGS protein.

1.5 RESEARCH GOALS AND SIGNIFICANCE

RGS proteins, specifically RGS4 and RGS5, appear to be rapidly turned over unless there are
specific mutations within the N-terminus130. Slight variations in the rapid turnover of RGS
proteins can affect the way GPCR signals are attenuated. For instance, if the presence of RGS2
within a cell was increased or decreased from basal levels, this would be expected to cause
GPCR signaling to be decreased or increased, respectively. In this study, our principal goal
was to examine the molecular mechanisms controlling the degradation of RGS2. These studies
were done in cellular in vitro models to establish a basic understanding of what is potentially
occurring at the molecular level. Our major goals were as follows:

i.

To determine the stability of wild-type and mutant forms of RGS2 (Study A)

ii.

To determine the effects of wild-type and mutant forms of RGS2 on G proteinmediated signaling (Study B)

1.5.1 STUDY A: STABILITY OF WILD-TYPE AND MUTANT FORMS OF RGS2 IN
VITRO

Regardless of the anticipated function of a protein, if it is targeted for degradation before it can
perform its task, it can be rendered useless. Evidence in our lab has shown that wild-type RGS2
is a rapidly degraded protein. Here we report that the use of alternative initiator methionine

32

residues alters the half-life of RGS2. Furthermore, mutations within the N-terminus of RGS2
also have severe effects on the half-life. We also provide evidence that RGS2 is degraded via
the ubiquitin-proteasome pathway. However, the degree to which expression levels change
depend on which initiator methionine is used or if RGS2 contains a SNP.
The objectives in this study were to:
1) Determine the effects of different methionine initiation sites and N-terminal
mutants on RGS2 stability
2) Determine the effects of inhibitors of degradation on RGS2 expression levels
1.5.2 STUDY B: EFFECTS OF WILD-TYPE AND MUTANT FORMS OF RGS2 ON Gαq/11
SIGNALING
RGS2 is known to attenuate Gαq/11 signaling but the degree to which each initiation variant can
inhibit signaling is unknown. Here we report that each initiation variant, as well as each RGS2
SNP, has an altered ability to attenuate Gαq/11 signaling compared to the full-length wild-type
RGS2.
The objective in this study was to:
1) Determine the effects of RGS2 methionine initiation sites and N-terminal mutants
on the ability to attenuate Gαq/11 signaling
Based on the results presented here, we propose that RGS2 is a rapidly degraded protein that
is usually degraded via the ubiquitin-proteasomal pathway. Which initiator methionine initiates
translation can have profound effects on the half-life of the protein and also the ability to
attenuate Gαq/11 signaling. Also, mutations within the N-terminus of RGS2 can alter the
protein’s half-life and ability to attenuate Gαq/11 signaling. Understanding the molecular
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mechanisms behind the regulation of RGS2 may provide insight into why individuals with
RGS2 mutations show the phenotypic profile they do.
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2

MATERIALS AND METHODS

2.1

CELL LINE

In vitro based studies using the well-established Human Embryonic Kidney 293 (HEK293)
cell line were used to assess how RGS2 is regulated. HEK293 cells are commonly used for in
vitro experiments due to their ease of transient transfection1. HEK293 cells were maintained
in Dulbecco’s Modified Eagle Medium (DMEM, Gibco Life Technologies) supplemented with
10% Fetal Bovine Serum (FBS, Gibco Life Technologies) at 37ºC with 5% CO2. Cells were
seeded every 48 or 72 h at a density of 2.2x106 or 0.8x106 cells, respectively, in 10 ml medium
in a 10 cm dish. Seeding density into smaller dishes were calculated depending on the surface
area (cm2) of the plate.
2.2

DNA CONSTRUCTS

A mammalian expression vector encoding full-length, C-terminally FLAG-tagged, wild-type
RGS2 in pcDNA3.1+ (Figure 2.1) was custom generated by the University of Missouri-Rolla
cDNA Resource Center (www.cdna.org). Mutant constructs derived from the initial plasmid
were generated in our laboratory. RGS2 M5V, RGS2 R14I, RGS2 K18N, and RGS2 G23D
were generated by performing QuikChange site-directed mutagenesis according to the
manufacturer’s protocol (Agilent, 200522). tM5 RGS2, tM16 RGS2, tM33 RGS2, RGS2 M5V,
RGS2 R14I, RGS2 K18N, and RGS2 G23D (Table 2.1) were amplified by polymerase chain
reaction (PCR) as Kpn1-Eco81I fragments in which the primers introduced the mutations.
Primers (Table 2.2) introduced a pseudo-Kozak sequence in the full length wild-type RGS2,
tM5 RGS2, tM16 RGS2, and tM33 RGS2. Plasmid DNA was purified using Qiagen Plasmid
Maxi Kit (Qiagen, 12163). FLAG-tagged 5-HTAR was a gift from Dr. Stephen Ferguson,
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Figure 2.1. Full-length wild-type RGS2 construct.
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Table 2.1. Amino acid sequence of RGS2 constructs

First 40 amino acids of RGS2 constructs with initiator methionines and mutations
FL-WT RGS2

MQSAMFLAVQ HDCRPMDKSA GSGHKSEEKR EKMKRTLLKD

tM5 RGS2

MFLAVQHDCR PMDKSAGSGH KSEEKREKMK RTLLKDWKTR

tM16 RGS2

MDKSAGSGHK SEEKREKMKR TLLKDWKTRL SYLFQNSSTP

tM33 RGS2

MKRTLLKDWK TRLSYFLQNS STPGKPKTGK KSKQQAFIKP

RGS2 M5V

MQSAVFLAVQ HDCRPMDKSA GSGHKSEEKR EKMKRTLLKD

RGS2 R14I

MQSAMFLAVQ HDCIPMDKSA GSGHKSEEKR EKMKRTLLKD

RGS2 K18N

MQSAMFLAVQ HDCRPMDNSA GSGHKSEEKR EKMKRTLLKD

RGS2 G23D

MQSAMFLAVQ HDCRPMDKSA GSDHKSEEKR EKMKRTLLKD

The first 40 amino acid residues for RGS2 constructs. Alternate start sites (initiation variants)
are highlighted in red. Point substitutions are highlighted in blue.
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Table 2.2. Primers for making wild-type RGS2 and its mutants

Construct
FL-WT RGS2

5’ primer

3’ primer

ACTAGTGGATCCGCCACCATGGCGCAAAGTGCTA

ACCGGTCGGTTCAAGTCTTCTTCTGA

TGTTCTTG

tM5 RGS2

ACTAGTGGATCCGCCACCATGGCGTTCTGGCTGT

ACCGGTCGGTTCAAGTCTTCTTCTGA

TCAACAC

tM16 RGS2

ACTAGTGGATCCGCCACCATGGCGGACAAGAGC

ACCGGTCGGTTCAAGTCTTCTTCTGA

GCAGGCAGT

tM33 RGS2

ACTAGTGGATCCGCCACCATGGCGAAACGGACCC

ACCGGTCGGTTCAAGTCTTCTTCTGA

TTTTAAAAGATTGG

RGS2 M5V

ACCATGCAAAGTGCTGTGTTCTTGGCTGTTC

GAACAGCCAAGAACACAGCACTTTGCATGGT

RGS2 R14I

TTCAACACGACTGCATACCCATGGACAAGAG

CTCTTGTCCATGGGTATGCAGTCGTGTTGAA

RGS2 K18N

CAGACCCATGGACAACAGCGCAGGCAGTGGC

GCCACTGCCTGCGCTGTTGTCCATGGGTCTG

RGS2 G23D

AGAGCGCAGGCAGTGACCACAAGAGCGAGGA

TCCTCGCTCTTGTGGTCACTGCCTGCGCTCT
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University of Western Ontario2. All sequences were confirmed using Robarts Research
Institute DNA Sequencing Facility.
2.3

TRANSFECTION

For immunoblotting, HEK293 cells were cultured in a 12-well plate under standard conditions
of 37ºC and 5% CO2, in DMEM with 10% FBS and transient transfections were performed
using Lipofectamine 2000 (Life Technologies, 11668-019) according to the manufacturer’s
protocol. To summarize the protocol, cells were seeded and grown to 70% confluence before
transfection. Once 70% confluent, 4 μl of Lipofectamine 2000 reagent was diluted into 100 μl
of Opti-MEM® I Reduced Serum Medium (Life Technologies, 31985-070) in an Eppendorf
tube. 1 μg plasmid DNA was diluted in a separate tube containing 100 μl of Opti-MEM® I
Reduced Serum Medium and both tubes were incubated at room temperature for 5 min. The
tubes were thoroughly mixed together and were incubated at room temperature for 20 min. The
combined mixture was added to the cells and allowed to incorporate into the cells for 24 h.
For inositol-phosphate turnover experiments, HEK293 cells were transiently transfected in
suspension and seeded in a 24-well plate. Briefly, 10 μl of Lipofectamine 2000 reagent was
diluted into 250 μl of Opti-MEM® I Reduced Serum Medium in an Eppendorf tube. 2 μg 5HT2AR plasmid DNA and either 2 μg RGS2 plasmid DNA or 2 μg pcDNA3.1+ DNA was
diluted in a separate tube containing 250 μl of Opti-MEM® I Reduced Serum Medium and
both tubes were incubated at room temperature for 5 min. The tubes were mixed thoroughly
together and were incubated at room temperature for 20 min. HEK293 cells from a 70%
confluent 10 cm plate were sedimented, mixed with 20 ml of fresh DMEM with 10% FBS and
the combined mixture of Opti-MEM®, Lipofectamine 2000, and plasmid DNA were added to
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the cells. Cells were seeded at 0.1 x 106 cells per well of a 24-well plate and were allowed to
incorporate into DNA for 24 h.
2.4

DRUG TREATMENT

24 h post-transfection, cells were treated with well-established pharmacological agents to
either inhibit proteasomal degradation or to attenuate global protein synthesis. HEK293 cells
were subjected to MG-132 (Sigma-Aldrich, M7449-200UL) (20 μM) treatment (2 h) in order
to inhibit the ubiquitin-proteasome pathway3. This was performed in parallel with 0.05%
DMSO (Fisher Scientific, D128-500) vehicle controls. HEK293 cells were subject to
cycloheximide (Sigma-Aldrich, C4859-1ML) (CHX, 20 μM) treatment over a period of 320
min in order to attenuate protein synthesis at varying times4. This was performed in parallel
with 0.05% DMSO vehicle controls.
2.5

PROTEIN ISOLATION

Cell lysates were prepared by washing twice with ice-cold 1X phosphate-buffered saline (PBS,
Fisher Scientific, BP399-4) (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, pH 7.4) and
scraped into 150 μl of ice-cold lysis buffer (250 mM NaCl, 50 mM Tris pH 8, 5 mM EDTA,
0.5% NP-40 (IGEPAL), phenylmethylsulfonyl fluoride protease inhibitor tablet (Roche,
04693116001), 20 mM Na4P2O7, 10 mM NaF, and 20 mM Na3VO4). Cell lysates were
homogenized by vigorous pipetting and underwent three consecutive freeze-thaw cycles via
flash freezing with liquid nitrogen. Pellets were sedimented by centrifugation at 11 000 x g for
15 min at 4ºC. Supernatants were collected and protein concentrations were determined using
Bradford Protein Assay (Bio-Rad, 500-0006).
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2.6

IMMUNOBLOTTING

Protein samples were prepared in 5X Laemmli loading (sample) buffer (60 mM Tris-HCl pH
6.8, 2% SDS, 10% glycerol, 5% β-mercaptoethanol, 0.02% bromophenol blue) and balanced
with 1X sample buffer for equal protein concentration. Samples were heated at 99ºC for 5 min
prior to gel loading and gel electrophoresis in order to denature the proteins. Equal amounts of
protein (20 μg) were separated by 12% SDS-PAGE and wet transferred onto PVDF membrane
(Millipore, IPVH00010). Membranes were incubated for 1 h in blocking buffer (Tris-buffered
saline, 0.1% Tween 20, 5% skim milk) and rocked at room temperature before overnight
incubation at 4ºC, rocking with either: anti-FLAG (1:1000, Sigma F3165) or anti-β tubulin for
protein loading control (1:1000, Pierce PA5-16863). Following overnight incubation,
membranes were washed 4 times for 5 min with TBST (Tris-buffered saline, 0.1% Tween 20)
and incubated for 1 h at room temperature with horseradish peroxidase-conjugated secondary
antibodies: anti-mouse IgG (1:5000, Pierce 31168) or anti-rabbit IgG (1:5000, Pierce 31463).
Immunoblots were then washed 4 times for 5 min with TBST. Immunoblots were visualized
with SuperSignal West Pico chemiluminescent substrate (Thermo Scientific, 34080) and
digitally imaged using Bio-Rad VersaDoc camera and Quantity One program (Bio-Rad, model
GS-700).
2.7

INOSITOL-PHOSPHATE TURNOVER

HEK293 cells were seeded in 24-well plates and transiently transfected with 5-HT2AR and
RGS2 plasmids as described in section 2.3 and the figure legends. Experiments were performed
according to previous protocols2,5. 24 h post-transfection, cells were incubated overnight in
500 μl serum-free DMEM with 1 μCi/ml myo-[3H]-inositol (PerkinElmer, NET1168001MC).
For all experiments, cells were incubated for 1 h in Hank’s Balance Salt Solution (HBSS –Life
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Technologies, 14025-092) (1.3 mM CaCl2, 0.5 mM MgCl2, 0.4 mM MgSO4, 5.3 mM KCl,
0.44 mM KH2PO4, 4.2 mM NaHCO3, 138 mM NaCl, 0.34 mM Na2HPO4, and 5.6 mM Dglucose) and were then incubated at 37ºC with 5% CO2 with 500 μl of 10 mM LiCl alone for
10 min followed by increasing doses of serotonin hydrochloride (Sigma-Aldrich, H952325MG) in 500 μl 10 mM LiCl for 30 min. Cells were placed on ice and the reaction was stopped
with 500 μl of 0.8 M perchloric acid and was neutralized with 400 μl of 0.72 M KOH, 0.6 M
KHCO3 overnight in 4ºC. Total cellular [3H]-inositol incorporation was determined in 50 μl of
cell lysate with 5 ml EcoLite(+)TM Liquid Scintillation Cocktail (MP Biomedicals,
0188247504). Total inositol phosphate was purified with 4 ml 0.1 M formic acid / 1 M
ammonium formate by anion exchange chromatography using 2 ml Dowex 1-X8 (formate
form) 200-400 mesh anion exchange resin6 (BioRad, 140-1454) after two consecutive 5 mL
water and 60 mM ammonium formate washes. [3H]-inositol phosphate formation was
determined by liquid scintillation in 15 ml EcoLite(+)TM Liquid Scintillation Cocktail using a
Beckman LS 5500 scintillation system and calculations are shown below.
2.8

DENSITOMETRY AND STATISTICAL ANALYSIS

Immunoblots for MG132 experiments were analyzed using densitometry software (Quantity
One, Bio-Rad) and expression levels were normalized to β-tubulin expression levels. Group
data are presented as means ±SEM. Data were compared by two-way analysis of variance
(ANOVA) and were further evaluated by Bonferroni post-test. Statistical analyses were
performed using GraphPad Prism® 5.0 and p-values of <0.05 were considered statistically
significant.
Immunoblots for CHX experiments were analyzed using Quantity One and expression levels
were normalized to β-tubulin expression levels. RGS2 protein (relative to β-tubulin) at each
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time point was normalized to the corresponding 0 time point. Group data are presented as
means ± SEM and are fit according to the one phase decay equation.
Y=(Yo – plateau)-kx + plateau
Statistical analyses were performed using GraphPad Prism® 5.0.
Percent conversion of [3H]-inositol to [3H]-inositol phosphates were solved using:
(DPM from column)(1.2/0.8) / (DPM in 50 μl)(1.2/0.05)
Where 1.2 = total neutralized cell extract (ml), 0.8 = 800 μl placed into the column, and 0.05
= 50 μl control cell extract. The data are representative of the mean ± SEM of three independent
experiments normalized to the largest value of 5-HT2AR + pcDNA3.1+ within the data set. Each
graph is representative of experiments done simultaneously. Thus, 5-HT2AR + pcDNA3.1+ and
5-HT2AR + FL-WT RGS2 experiments were performed with the corresponding conditions in
each of the graphs. Dose-response curves were fit by using nonlinear regression specifically
the sigmodal dose-response equation was used:
Y = Bottom + (Top-Bottom) / (1 + 10logEC50-x)
This equation is also referred to as a three-parameter logistic equation. The bottom value of
each graph was constrained to a common value for all data sets. EC50 values were compared
by one-way analysis of variance (ANOVA) and were further evaluated by Bonferroni posttest. All analyses were performed using GraphPad Prism® 5.0.
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3

RESULTS

3.1

STABILITY OF WILD-TYPE AND MUTANT FORMS OF RGS2 IN VITRO

Due to the importance of RGS2 within a cell, we were particularly interested in determining
the half-life of full-length wild-type RGS2 as well as the half-lives of different point mutations
and alternative initiation variants. Differences in the half-lives of various RGS2 constructs
compared to the full-length wild-type form may underlie corresponding differences in GPCR
signaling levels; a longer RGS2 half-life could result in greater GPCR signal attenuation.
3.1.1 RGS2 SNPS AFFECT PROTEIN TURNOVER RATE
Cycloheximide (CHX) is a well-established blocker of translational elongation and thus it acts
as an inhibitor of protein synthesis1. This property allows for the determination of the half-life
of a protein of interest1. The half-life of a protein is taken as the time after CHX addition for it
to be reduced by 50% from baseline levels. Transfected HEK293 cells were treated with CHX
at different time points, lysed simultaneously, and subject to immunoblotting. RGS2 levels
were normalized to β-tubulin due to its abundance within a cell and long half-life of ~50 h.
Full-length wild-type RGS2 was found to have a half-life of 17.7 ± 6.5 min (Figure 3.1). RGS2
M5V, RGS2 G23D, RGS2 R14I, and RGS2 K18N mutations were found to have half-lives of
10.3 ± 3.7, 34.7 ± 9.7, 6.3 ± 1.4, and 13.0 ± 4.7 min, respectively (Figure 3.1-Figure 3.5). The
gray line represents the full-length wild-type RGS2 degradation curve for comparison (Figure
3.2-3.5). The half-life of full-length wild-type RGS2 is consistent with the findings of a
previous group who reported it to be 17.5 ± 5.8 min2. Simply by increasing or decreasing the
turnover time of RGS2 could have significant effects on GPCR signaling. RGS2 M5V
appeared to have a shorter half-life than full-length wild-type RGS2, which may be why there
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is a possible association between this SNP and hypertension; Gα signaling is not being
attenuated to the same degree. In contrast, RGS2 G23D appeared to have a half-life nearly
double that of the full-length wild-type protein. This suggests that Gα signaling could be
attenuated more efficiently in someone with this mutation compared to the wild-type RGS2.
This may explain why individuals with this mutation develop pathophysiological conditions
synonymous with decreased Gαs signaling. RGS2 R14I had a much shorter half-life than fulllength wild-type RGS2 whereas RGS2 K18N had a similar half-life. Though neither of these
SNPs is associated with any known phenotype, it would be interesting to screen individuals
with the RGS2 R14I mutation to see if they have a hypertensive phenotype. The mechanism
for why we see altered levels due to one point mutation remains unknown. However, it may
be due to the specific amino acids mutated or located near the mutation affecting degradation
via the N-end rule.
3.1.2 RGS2 INITIATION VARIANTS EXHIBIT DIFFERNT PROTEIN TURNOVER
RATES
RGS2 contains four different initiator methionine residues, all of which can serve as the points
for the initiation of translation3. It is important to determine if each initiation variant causes a
change in half-life compared to the full length wild-type RGS2, as their relative levels could
conceivably vary depending on cellular conditions4. Unfortunately, we were unable to
determine the half-life of tM5 RGS2 due to minimal detectability of this protein construct at
basal levels; this was further exacerbated by CHX treatment (Figure 3.8). tM16 RGS2 and
tM33 RGS2 had half-lives of 34.5 ± 1.8 and 17.3 ± 4.3 min, respectively (Figure 3.6-Figure
3.7). These results suggest that tM5 RGS2 is highly unstable intracellularly, and is likely
degraded at a rate that results in barely measureable protein levels. tM16 RGS2 exhibited
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Figure 3.1. Full-length wild-type RGS2 degradation curve (A) effect of 20 μM cycloheximide
(CHX) or vehicle (DMSO) treatment over a period of 320 minutes (n=5). RGS2 protein
(relative to β-tubulin) at each time point was normalized to the corresponding 0 minute time
point. The resultant half-life of full-length wild-type RGS2 is 17.7 ± 6.5 minutes. (B)
Representative immunoblots of full-length wild-type RGS2 after treatment with CHX or
vehicle. The first panel represents full-length wild-type RGS2 treated with CHX and the second
panel represents the analogous β-tubulin treated with CHX. The lower two immunoblots
represent full-length wild-type RGS2 in cells treated with DMSO at 0.05% and cells treated
with DMSO and probed for β-tubulin.
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Figure 3.2. RGS2 M5V degradation curve (A) effect of 20 μM cycloheximide (CHX) or
vehicle (DMSO) treatment over a period of 320 minutes (n=5). RGS2 protein (relative to βtubulin) at each time point was normalized to the corresponding 0 minute time point. The
resultant half-life of RGS2 M5V 10.3 ± 3.7 minutes. The gray line represents full-length wildtype RGS2 degradation in Figure 3.1. (B) Representative immunoblots of RGS2 M5V after
treatment with CHX or vehicle. The first panel represents RGS2 M5V treated with CHX and
the second panel represents the analogous β-tubulin treated with CHX. The lower two
immunoblots represent RGS2 M5V in cells treated with DMSO at 0.05% and cells treated with
DMSO and probed for β-tubulin.
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Figure 3.3. RGS2 G32D degradation curve (A) effect of 20 μM cycloheximide (CHX) or
vehicle (DMSO) treatment over a period of 320 minutes (n=4). RGS2 protein (relative to βtubulin) at each time point was normalized to the corresponding 0 minute time point. The
resultant half-life of RGS2 G23D 34.7 ± 9.7 minutes. The gray line represents full-length wildtype RGS2 degradation in Figure 3.1. (B) Representative immunoblots of RGS2 G23D after
treatment with CHX or vehicle. The first panel represents RGS2 G23D treated with CHX and
the second panel represents the analogous β-tubulin treated with CHX. The lower two
immunoblots represent RGS2 G23D in cells treated with DMSO at 0.05% and cells treated
with DMSO and probed for β-tubulin.
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Figure 3.4. RGS2 R14I degradation curve (A) effect of 20 μM cycloheximide (CHX) or
vehicle (DMSO) treatment over a period of 320 minutes (n=4). RGS2 protein (relative to βtubulin) at each time point was normalized to the corresponding 0 minute time point. The
resultant half-life of RGS2 R14I 6.3 ± 1.4 minutes. The gray line represents full-length wildtype RGS2 degradation in Figure 3.1. (B) Representative immunoblots of RGS2 R14I after
treatment with CHX or vehicle. The first panel represents RGS2 R14I treated with CHX and
the second panel represents the analogous β-tubulin treated with CHX. The lower two
immunoblots represent RGS2 R14I in cells treated with DMSO at 0.05% and cells treated with
DMSO and probed for β-tubulin.
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RGS2 K18N protein/ -tubulin (%)

A

RGS2 K18N CHX
RGS2 K18N DMSO
Full-length wild-type RGS2

100

50

0
0

100

200

300

Time (mins)

B
Time (min)

0

5

25 kDa

10

20 40

80 160 320
RGS2 K18N - CHX

55 kDa

β-tubulin - CHX

25 kDa

RGS2 K18N -DMSO

55 kDa

β-tubulin - DMSO

Figure 3.5. RGS2 K18N degradation curve (A) effect of 20 μM cycloheximide (CHX) or
vehicle (DMSO) treatment over a period of 320 minutes (n=4). RGS2 protein (relative to βtubulin) at each time point was normalized to the corresponding 0 minute time point. The
resultant half-life of RGS2 K18N 13.0 ± 4.7 minutes. The gray line represents full-length wildtype RGS2 degradation in Figure 3.1. (B) Representative immunoblots of RGS2 K18N after
treatment with CHX or vehicle. The first panel represents RGS2 K18N treated with CHX and
the second panel represents the analogous β-tubulin treated with CHX. The following
immunoblot represents RGS2 K18N in cells treated with DMSO at 0.05% and cells treated
with DMSO and probed for β-tubulin.
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Figure 3.6. tM16 RGS2 degradation curve (A) effect of 20 μM cycloheximide (CHX) or
vehicle (DMSO) treatment over a period of 320 minutes (n=5). RGS2 protein (relative to βtubulin) at each time point was normalized to the corresponding 0 minute time point. The
resultant half-life of tM16 RGS2 34.5 ± 1.8 minutes. The gray line represents full-length wildtype RGS2 degradation in Figure 3.1. (B) Representative immunoblots of tM16 RGS2 after
treatment with CHX or vehicle. The first panel represents tM16 RGS2 treated with CHX and
the second panel represents the analogous β-tubulin treated with CHX. The lower two
immunoblots represent tM16 RGS2 in cells treated with DMSO at 0.05% and cells treated with
DMSO and probed for β-tubulin.
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Figure 3.7. tM33 RGS2 degradation curve (A) effect of 20 μM cycloheximide (CHX) or
vehicle (DMSO) treatment over a period of 320 minutes (n=3). RGS2 protein (relative to βtubulin) at each time point was normalized to the corresponding 0 minute time point. The
resultant half-life of tM33 RGS2 17.3 ± 4.3 minutes. The gray line represents full-length wildtype RGS2 degradation in Figure 3.1. (B) Representative immunoblots of tM33 RGS2 after
treatment with CHX or vehicle. The first panel represents tM33 RGS2 treated with CHX and
the second panel represents the analogous β-tubulin treated with CHX. The lower two
immunoblots represent tM33 RGS2 in cells treated with DMSO at 0.05% and cells treated with
DMSO and probed for β-tubulin.
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Figure 3.8. tM5 RGS2 Degradation. tM5 RGS2 was treated with CHX over 320 min. The
figure represents the only instance out of 8 experiments in which tM5 RGS2 was detectable.
Treatment with CHX further exacerbated the limited detection. Thus, the half-life for tM5
RGS2 could not be determined.
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approximately double the half-life of full-length RGS2, whereas tM33 RGS2 showed a halflife comparable to full-length RGS2. The mechanism underlying these different half-lives
remains unknown, but may reflect altered recognition by the ubiquitin-ligase enzymes which
attach ubiquitin proteins for recognition by proteasomes. It might be advantageous to take a
closer look at the amino acids near the N-terminus of each construct; it has been suggested that
some specific amino acids are more likely to support degradation than others5–9. It should also
be noted that tM16 RGS2 in some experiments increased in expression at the 5 and 10 min
time points compared to the non-treated lysates. Cellular stress is known to increase RGS2
mRNA and protein expression10. However, this only seemed to occur in the tM16 RGS2
construct. tM33 RGS2 had a half-life comparable to that of full-length wild-type RGS2
suggesting that there is not a need for this initiation variant to be upregulated.
3.2 DEGRADATION PATHWAY FOLLOWED BY RGS2
Due to the altered half-lives associated with RGS2 mutations and initiation variants, we were
particularly interested in determining how RGS2 is degraded. The most common intracellular
protein degradation pathway is the ubiquitin-proteasome pathway, where ubiquitin is added to
a protein that is then recognized by the proteasome and ultimately degraded. This is a rapid,
common process, and by inhibiting the pathway, we can determine if levels of RGS2 are
changed via this route.
3.2.1 INHIBITION OF PROTEASOMAL DEGRADATION ALTERS CELLULAR LEVELS
OF WILD-TYPE RGS2 AND THE MAJORITY OF RGS2 SNPS
MG132 is a well-established peptide aldehyde that can inhibit many types of proteases11–13.
Due to this property, MG132 is considered a proteasome inhibitor and has been used
extensively to determine whether a particular protein is degraded via proteasomes11–14. If the
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expression level of a protein increases upon MG132 treatment, it suggests that under normal
conditions, the protein is degraded by the ubiquitin-proteasome pathway. Transfected HEK293
cells were subjected to MG132 or DMSO (vehicle) treatment for 2 h, lysed, and
immunoblotted. Full-length wild-type RGS2 as well as RGS2 M5V expression increased when
cells were treated with MG132 (Figure 3.9). However, RGS2 G23D levels did not change upon
MG132 treatment (Figure 3.9). This result was unexpected as we hypothesized that each RGS2
construct would increase expression level in the presence of MG132. It is interesting to note
that RGS2 G23D had a longer half-life than full length wild-type RGS2 (Figure 3.3). This
could be attributed to RGS2 G23D being more stable intracellularly. It would thus appear not
be degraded by the ubiquitin-proteasome pathway. Ultimately, our results demonstrate that
full-length wild-type RGS2 levels increase in the presence of a proteasome inhibitor. This
suggests that under basal conditions, RGS2 is rapidly degraded by proteasomes.
Analogous experiments were performed with RGS2 R14I and RGS K18N. Transfected
HEK293 cells were subject to MG132 or DMSO treatment. Full-length wild-type RGS2 was
again significantly increased when treated with MG132. RGS2 R14I and RGS2 K18N were
also increased with MG132 treatment (Figure 3.10). RGS2 R14I and RGS2 K18N were found
to have half-lives respectively shorter than and comparable to full-length wild-type RGS2, and
taken together the data suggest that these RGS2 SNPs could also be degraded via the ubiquitinproteasomal pathway. These results suggest that under basal conditions, RGS2 is rapidly
degraded via proteasomes and inhibiting these proteasomes significantly increases intracellular
levels of RGS2.
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Figure 3.9. RGS2 expression in the absence or presence of MG132. (A) Effect of 2 h, 20 μM
MG132 (proteasome inhibitor) treatment and single point mutations on cellular levels of
FLAG-tagged RGS2 constructs, normalized to β tubulin (n=4). Group data are presented as
means ± SEM. Data were compared by two-way analysis of variance (ANOVA) and were
further evaluated by Bonferroni post-test. Observed levels of RGS2 WT and RGS2 M5V
**p<0.01 and ***p<0.001, respectively. (B) Representative immunoblot of mutant RGS2
constructs in the absence and presence of MG132
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Figure 3.10. RGS2 expression in the absence or presence of MG132. (A) Effect of 2 h, 20 μM
MG132 (proteasome inhibitor) treatment and single point mutations on cellular levels of
FLAG-tagged RGS2 constructs, normalized to β tubulin (n=5). Group data are presented as
means ± SEM. Data were compared by two-way analysis of variance (ANOVA) and were
further evaluated by Bonferroni post-test. Observed levels of RGS2 WT, RGS2 R14I, RGS2
K18N ***p<0.001, and *p<0.05. (B) Representative immunoblot of mutant RGS2 constructs
in the absence and presence of MG132
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3.2.2 INIHIBITION OF PROTEASOMAL DEGRADATION INCREASES CELLULAR
LEVELS OF ALL RGS2 INITIATION VARIANTS
Similar to our experiments on the mutant forms of RGS2, we examined whether the different
initiation site variants had altered expression levels in the presence of MG132. A pseudoKozak sequence was placed before each methionine to ensure that the methionine of interest
was initiating translation. Independent of which initiation variant was produced, the relative
levels of protein increased with MG132 treatment (Figure 3.11). This result is consistent with
the half-life experiments, where tM16 RGS2 had a much longer half-life than the other
constructs (Figure 3.6).

3.3 INOSITOL-PHOSPHATE TURNOVER
Further studies were carried out to determine whether the altered half-lives of RGS2 mutations
and initiation variants might correspond to any effect on the ability of RGS2 to attenuate Gαq/11
signaling. Wild-type RGS2 has been reported to attenuate Gαq/11 signaling15. It is possible that
RGS2 mutations or initiation variants may differ from the full-length wild type protein in their
abilities to attenuate Gαq/11 signaling, however relatively few alternate forms of RGS2 have
been tested.

72

A

WT RGS2

B
MG132

-

+

tM5 RGS2
-

+

tM16 RGS2

tM33 RGS2

-

-

+

+

25 kDa

RGS2

55 kDa

β-tubulin

Figure 3.11. RGS2 expression in the absence or presence of MG132. (A) Effect of 2 h, 20 μM
MG132 treatment on full-length RGS2 and truncations prior to each initiator methionine
residue on the cellular levels of FLAG-tagged RGS2 constructs, normalized to β tubulin (n=5).
Group data are presented as means ± SEM. Data were compared by two-way analysis of
variance (ANOVA) and were further evaluated by Bonferroni post-test. Observed levels of full
length wild-type RGS2, and variants with a pseudo-Kozak sequence prior to M5, M16 and
M33 all increased in the presence of MG132, ***p<0.001, **p<0.01, and *p<0.05. (B)
Representative immunoblot of full-length wild-type RGS2 expression and truncation mutants
in the absence and presence of MG132.
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3.3.1 RGS2 SNPS AFFECT Gαq/11 SIGNAL ATTENUATION
IP3 is generated by the activation of phospholipase Cβ by Gαq/11. However, it is a challenge to
measure IP3 levels due to its rapid turnover16. Fortunately, IP3 is broken down into inositolphosphates which are stable in the presence of lithium and can be measured using a wellestablished technique16,17. Inhibitory effects of RGS proteins on Gαq/11-PLC-β signaling are
manifested as decreases in GPCR agonist potency and/or maximal effect. HEK293 cells
transiently transfected with plasmid encoding the 5-HT2AR were loaded with myo-[3H]inositol overnight and then stimulated with increasing concentrations of 5-HT. Full-length
wild-type RGS2 (EC50 = 0.28 ± 0.18 μM) as well as RGS2 M5V (EC50 = 0.084 ± 0.032 μM)
and RGS2 G23D (EC50 = 0.75 ± 0.68 μM) each yielded a rightward shift in the 5-HT doseresponse curve compared to the 5-HT2AR (EC50 = 0.066 ± 0.036 μM) by itself (Figure 3.12).
Though RGS2 M5V yielded a rightward shift, it is much smaller than the effect of full-length
wild-type RGS2 suggesting that this construct has decreased stability. The greater rightward
shift of RGS2 G23D suggests that this construct has an increased ability to attenuate 5-HT2AR
compared to full-length wild-type RGS2, consistent with its slower degradation. The reduced
Emax observed in cells transfected with RGS2 G23D, along with the increased EC50, imply
decreased receptor reserve with RGS2 G23D present. Ultimately, our results show that 1)
RGS2 has the ability to attenuate the Gαq/11 coupled 5-HT2AR alone and 2) mutations within
the N-terminus of RGS2 affect the degree to which it can attenuate Gαq/11 signaling.
An analogous set of experiments was performed using two other RGS2 mutants, RGS2 R14I
and RGS2 K18N. Both RGS2 R14I (EC50 = 0.28 ± 0.15 μM) and RGS2 K18N (EC50 = 0.50 ±
0.23 μM) yielded a rightward shift in the dose-response curve compared to 5-HT2AR alone
(EC50 = 0.065 ± 0.025 μM) (Figure 3.13). This suggests that both of these RGS2 constructs
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Figure 3.12. Stimulation of phospholipase Cβ activity by 5-HT2AR signaling. Dose response
curve for 5-HT mediated IP formation in response to treatment with increasing concentrations
of 5-HT for 30 minutes in HEK293 cells transfected with a total of 2 μg of plasmid DNA
expressing 5-HT2AR, plus either an RGS2 construct, or pcDNA3.1 as a transfection control.
The data shown are the means ± S.E.M. of three independent experiments. For each
experiment, during the fitting procedure the lower asymptote was constrained to be equal for
all four data sets. The resultant fitted parameters were then averaged for each of the four
experimental conditions and used to generate the lines shown. The EC50 for 5-HT2AR-mediated
IP formation in the absence of transfected RGS2 was found to be 0.066 ± 0.036 μM, whereas
the corresponding values with full-length wild-type RGS2, RGS2 M5V, and RGS2 G23D were
found to be 0.28 ± 0.18 μM, 0.084 ± 0.032 μM, and 0.75 ± 0.68 μM, respectively. EC50 values
were compared by one-way analysis of variance (ANOVA) and were further evaluated by
Bonferroni post-test. Observed EC50 values for 5HT2AR + FL-RGS2 and 5HT2AR + RGS2
G23D compared to 5HT2AR + pcDNA3.1 increased, p<0.01 and p<0.001, respectively.
5HT2AR + RGS2 M5V did not significantly change (p>0.05).
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Figure 3.13. Stimulation of phospholipase Cβ activity by 5-HT2AR signaling. Dose response
curve for 5-HT mediated IP formation in response to treatment with increasing concentrations
of 5-HT for 30 minutes in HEK293 cells transfected with a total of 2 μg of plasmid DNA
expressing 5-HT2AR, plus either an RGS2 construct, or pcDNA3.1 as a transfection control.
The data shown are the means ± S.E.M. of three independent experiments. For each
experimental, during the fitting procedure the lower asymptote was constrained to be equal for
all four data sets. The resultant fitted parameters were then averaged for each of the four
experimental conditions and used to generate the lines shown. The EC50 for 5-HT2AR-mediated
IP formation in the absence of transfected RGS2 was found to be 0.065 ± 0.25 μM, whereas
the corresponding values with full-length wild-type RGS2, RGS2 R14I and RGS2 K18N were
found to be 0.55 ± 0.25 μM, 0.19 ± 0.15 μM and 0.50 ± 0.23 μM, respectively. EC50 values
were compared by one-way analysis of variance (ANOVA) and were further evaluated by
Bonferroni post-test. Observed EC50 values for 5HT2AR + FL-RGS2, 5HT2AR + RGS2 R14I,
and 5HT2AR + RGS2 K18N compared to 5HT2AR + pcDNA3.1 increased, p<0.001, p<0.01,
and p<0.001, respectively.
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are able to attenuate Gαq/11 signaling but to different degrees. RGS2 K18N, which had a halflife comparable to that of full-length wild-type RGS2, also had a similar log EC50 value to the
wild-type construct (EC50 = 0.55 ± 0.25 μM). These results, along with the RGS2 M5V and
RGS2 G23D experiments, suggest that the ability of RGS2 to attenuate Gαq/11 can depend on
the half-life of the protein as the constructs with the longer half-lives (e.g., RGS2 G23D) tended
to produce greater rightward shifts in the 5-HT dose-response curve.
3.3.2 RGS2 INITIATION VARIANTS AFFECT Gαq/11 SIGNAL ATTENUATION
Experiments analogous to those performed using the RGS2 mutations (Section 3.2.1) were also
performed with the four RGS2 initiation variants. Regardless of which RGS2 construct was
transfected with 5-HT2AR, there was a rightward shift in the EC50 (Figure 3.14), including the
minimal shift with that tM5 RGS2 construct that had an immeasurably short half-life. The EC50
values of 5-HT in cells transfected with the 5-HT2AR plus full-length RGS2, tM5 RGS2, tM16
RGS2, and tM33 RGS2 were found to be 0.27 ± 0.17 μM, 0.11 ± 0.04 μM, 0.67 ± 0.60 μM,
and 0.46 ± 0.30μM respectively, compared to 0.072 ± 0.035 μM for 5-HT2AR alone. The
rightward shifts in these dose-response curves suggest that independent of which initiation site
is used, RGS2 has the ability to attenuate Gαq/11 coupled receptor signaling, but to varying
extents. The degree to which RGS2 attenuates receptor signaling is roughly proportional to the
half-life of a given initiation variant, as shown in Section 3.1.2. For example, tM5 RGS2 had
an immeasurably short half-life (<5 min) and was the least able to attenuate inositol-phosphate
formation, whereas tM16 RGS2 had the longest half-life (34.5 min) and also had the greatest
ability to attenuate inositol phosphate formation and even lowered the Emax.
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Figure 3.14. Stimulation of phospholipase Cβ activity by 5-HT2AR signaling. Dose response
curve for 5-HT mediated IP formation in response to treatment with increasing concentrations
of 5-HT for 30 minutes in HEK293 cells transfected with a total of 2 μg of plasmid DNA
expressing 5-HT2AR, plus either an RGS2 construct, or pcDNA3.1 as a transfection control.
The data shown are the means ± S.E.M. of three independent experiments. For each
experimental, during the fitting procedure the lower asymptote was constrained to be equal for
all four data sets. The resultant fitted parameters were then averaged for each of the four
experimental conditions and used to generate the lines shown. The EC50 for 5-HT2AR-mediated
IP formation in the absence of transfected RGS2 was found to be0.072 ± 0.035 μM, whereas
the corresponding values with full-length RGS2, tM5 RGS2, tM16 RGS2, and tM33 RGS2
0.27 ± 0.17 μM, 0.11 ± 0.04 μM, 0.67 ± 0.60 μM, 0.46 ± 0.30 μM respectively. EC50 values
were compared by one-way analysis of variance (ANOVA) and were further evaluated by
Bonferroni post-test. Observed EC50 values for 5HT2AR + FL-RGS2, 5HT2AR + tM16 RGS2,
and 5HT2AR + tM33 RGS2 compared to 5HT2AR + pcDNA3.1 increased, p<0.01, p<0.001,
and p<0.01, respectively. 5HT2AR + tM5 RGS2 did not significantly change (p>0.05).
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3.3.3 CORRELATION BETWEEN RGS2 AND Gαq/11 SIGNAL ATTENUATION
We wanted to determine if there was a correlation between the half-life of RGS2 constructs
and their abilities to attenuate Gαq/11 signaling. The average half-life and EC50 values from
Sections 3.1 and 3.2, respectively, were graphed (Figure 3.15). tM5 RGS2 was arbitrarily
given a half-life of 5 min due to our inability to consistently detect this construct via
immunoblotting (Figure 3.8). There appears to be a correlation between the half-life and EC50
in that as the half-life increases, so does the EC50. This suggests that when RGS2 is more stable
in a cell, it also functions to attenuate signal to a greater degree. It should be noted that this is
not a perfect correlation (r2 = 0.8004). The low r2 value could be due to inter-experimental
variability and/or differences in translation efficiency between RGS2 variants.
To summarize, our data reveal that small changes in the amino acid sequence of RGS2 can
have substantive effects on its rate of degradation, and thus on its ability to regulate signaling.
Simply mutating one amino acid in the N-terminal region of RGS2 can alter its half-life, which
in turn can affect the ability of the protein to attenuate Gαq/11 signaling. For instance, RGS2
M5V was shown to have a half-life shorter than full-length wild-type RGS2 (Figure 3.2) which
may result in the decreased ability to attenuate Gαq/11 signaling (Figure 3.12). The opposite
outcome was seen for the most stable variant tested, RGS2 G23D (Figure 3.3). Additionally,
the majority of RGS2 construct’s intracellular levels increased with proteasomal inhibition
suggesting, that under basal conditions, RGS2 is degraded via the ubiquitin proteasomal
pathway (Figure3.9-Figure 3.11).
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Figure 3.15. Correlation between half-life and EC50. Positive correlation between the average
half-life of an RGS2 construct and the EC50 of 5-HT in cells expressing 5-HT2AR plus the given
RGS2 variant. tM5 RGS2 was arbitrarily assigned a half-life of 5 min. Data shown are
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4

DISCUSSION

4.1

SUMMARY OF NOVEL FINDINGS AND CONCLUSIONS

Although recent studies have indicated that RGS2 contains multiple initiation sites1 and can
contain numerous SNPs2,3, it is unknown whether these different isoforms have any effect on
RGS2 regulation. Our data suggest that even minor changes in the N-terminus of RGS2 can
have a profound effect on RGS2 regulation. We show for the first time altered degradation
rates between RGS2 initiation variants and also RGS2 mutations. Additionally, the altered
half-lives appear to be causing differences in RGS2 mediated Gαq/11 signal attenuation.
Furthermore, we present data suggesting that RGS2 is rapidly degraded via the ubiquitinproteasome pathway. The altered degradation rates may be due to how quickly each RGS2
protein is recognized and degraded via the ubiquitin-proteasome pathway. Since RGS2 is a
ubiquitously expressed protein and regulates the signaling of many GPCRs, it is most prudent
to understand how any changes within the N-terminus of RGS2 could have significant effects
on Gα signaling.

Study A: To determine the stability of wild-type and mutant forms of RGS2.

We demonstrated that the use of each initiator methionine residue alters the half-life of RGS2.
Furthermore, mutations within the N-terminal region of RGS2 also have a strong impact on
protein half-life. This becomes important when one considers the major biological function
RGS2 has within a cell, which is to attenuate Gα signaling. We also presented evidence
suggesting that under basal conditions, wild-type RGS2 is rapidly degraded via the ubiquitinproteasome pathway. This holds true regardless of which initiator methionine begins
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translation. It also appears the mutant forms of RGS2 are degraded via the same pathway with
exception to RGS2 G23D. It was interesting that the RGS2 mutant with the longest half-life,
RGS2 G23D, was unaffected by MG132 treatment. MG132 is a nonspecific inhibitor of the
ubiquitin-proteasome pathway meaning when the drug is present within a cell, the vast majority
proteins that are degraded in such a fashion should increase in cellular abundance. Individuals
carrying this point substitution have a phenotypic profile including borderline IQ, hirsutism,
increased bone alkaline phosphatase and decreased platelet Gαs function; all phenotypes
indicative of decreased Gαs signaling3. It has been shown that RGS2 G23D causes a
preferential shift in translation to the two longest isoforms of RGS2 which contains a putative
adenylyl cyclase binding domain3. Since RGS2 G23D levels were unaffected by proteasome
inhibition and had an increased half-life relative to full-length wild-type RGS2 levels, it would
be reasonable to assume these attributes of the point substitution are what is leading to such a
robust phenotype. Gα signaling is undoubtedly an important signaling pathway and if an RGS2
mutant attenuates the signal to a greater degree than what is expected, one would anticipate
some sort of physiological complication.

Study B: To determine the effects of wild-type and mutant forms of RGS2 on G proteinmediated signaling

We showed that an increase or decrease in the half-life of RGS2 compared to the full-length
wild-type RGS2 was respectively proportional to an increase or decrease in Gαq/11 signal
attenuation (Figure 3.15). Interestingly, RGS2 M5V and RGS2 G23D, which have been
associated with physiological consequences, had a respective decrease or increase in the ability
to attenuate Gαq/11-mediated signaling (Figure 3.12). Furthermore, RGS2 initiation variants
had altered abilities to mitigate Gαq/11 signaling (Figure 3.14) proportional to the half-lives
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determined in Study A. Therefore, individuals carrying a mutant form of RGS2 may experience
phenotypes associated with Gα signaling, not because RGS2 is ineffective but because the
altered half-life of RGS2 has caused a shift in the expected degree of Gα signaling.

4.2 CONTRIBUTIONS OF RESEARCH TO CURRENT STATE OF KNOWLEDGE

GPCRs are an integral part of signaling systems, allowing extracellular signals from a broad
range of ligands to be turned into intracellular responses4. Excessive GPCR signaling can lead
to many pathophysiological conditions including hypertension5, stress, anxiety, depression6,
and many endocrine disorders7. It is therefore necessary to have well regulated mechanisms
for GPCR deactivation. There are intrinsic mechanisms for GPCR deactivation 8 but this
process can be accelerated by GAPs such as RGS proteins, and indeed RGS proteins in many
instances are necessary for normal signaling to take place9. There are many RGS proteins each
with variable tissue distribution profiles, Gα protein specificity, and all must have mechanisms
for regulation. For example, RGS4 and RGS5 have been extensively researched and they both
have been identified as proteins that are rapidly degraded via the ubiquitin proteasome
pathway10,11. We have shown that wild-type RGS2 is likely degraded in the same fashion,
although its degradation is somewhat less rapid than occurs with RGS4 and RGS511. We have
also shown that the N-terminus of RGS2 is important in determining how it is regulated.
Previous research showed that truncation of the N-terminus of RGS2 results in loss of function,
suggesting that the N-terminus may have a role in plasma membrane targeting12. We indicated
that N-terminal modifications, whether due to the use of initiation variants or introducing
mutations, can have severe effects on RGS2 regulation and therefore, G protein signal
attenuation. The N-end rule is only interested in the first two amino acids yet we found
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substitutions farther into the N-terminus had profound effects on degradation. This concept
will be discussed in Section 4.3.
Individuals carrying certain RGS2 SNPs show particular phenotypes2,3 but it remains unknown
as to why these pathological consequences occur. RGS2 M5V has been tentatively associated
with hypertension2 but the evidence is not yet compelling due in part to the low population
frequency of the SNP. However, our data suggest that RGS2 M5V has a relatively short halflife compared to the full-length wild-type RGS2 and also has a decreased ability to attenuate
Gαq/11 signaling, which might be expected to result in increased Gαq/11 signaling. Excessive
Gαq/11 signaling is a factor which can lead to hypertension and eventually cardiac
hypertrophy13. Knowing this allows our data to strengthen the hypothesis that RGS2 M5V may
be associated with hypertension. Interestingly, there is a genetic defect called
Bartter’s/Gitelman’s syndrome where individuals have the classic characteristics of
hypertension (activation of the renin-angiotensin-aldosterone system, increased angiotensin II
and aldosterone, hypokalemia, and sodium depletion), yet are normo/hypotensive due in part
to increased cellular RGS2 levels14. Individuals carrying the RGS2 G23D mutation have a
phenotypic profile including borderline IQ, hirsutism, increased bone alkaline phosphatase,
and decrease platelet Gαs function, all characteristics seen in patients with a Gαs hypofunction
condition known as Albright hereditary osteodystrophy (AHO)3. The authors concluded that
this mutant RGS2 protein has an increased inhibitory effect on cAMP production due to a
preference of the ribosomal machinery for translation initiation sites 1 and 5, which contain a
putative adenylyl cyclase binding domain at amino acids 9-113. Our data is consistent with the
idea that RGS2 G23D will have an increased ability to inhibit Gα signaling but it may be more
complex than the use of differential initiation sites. Based on the findings presented in this
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thesis, we propose that RGS2 G23D has an increased half-life relative to the full-length wildtype form of RGS2 which will present a greater chance of RGS2 binding and inhibiting Gαmediated signals; this phenomenon will only enhance the tendency towards decreased Gαs (and
Gαq/11) signaling in individuals who harbour the RGS2 G23D point mutation.

We also investigated two other RGS2 mutations with no known phenotypes, RGS2 R14I and
RGS2 K18N (genecards.org). Our findings with these mutations reinforce our other findings
which suggest that the half-life of an RGS2 protein is proportional to the ability to inactivate
Gαq/11 signaling. RGS2 R14I had a relatively short half-life of ~6 minutes. It would be
interesting to determine if individuals with this mutation present any phenotypes associated
with excessive Gα signaling, such as hypertension. RGS2 K18N on the other hand has a halflife comparable to full-length wild-type RGS2 and the only research done on this SNP shows
it is not associated with hypertension15. This would seem reasonable as this mutation has a
nearly identical ability to attenuate Gαq/11 signaling as full-length wild-type RGS2. Overall,
our data shows how important the N-terminus is within RGS2 and any manipulation in the
amino acid sequence can affect how RGS2 is regulated and how it functions.

4.3 RGS2 IS DEGRADED VIA THE UBIQUITIN-PROTEASOME PATHWAY

Previous research has suggested that like RGS4 and RGS5, RGS2 may be degraded via the
ubiquitin-proteasome pathway10,16. Our results propose that this hypothesis is correct at least
for most variants of RGS2. Figure 1.5 shows the classical N-end rule pathway, where the amino
acid next to the initiator methionine is imperative in predicting if, and how rapidly, the protein
is ubiquitinated and degraded. It is unknown at what rate each process happens, for example,
whether deamidation by NTAN NtN-amidase is quicker than NTAQ NtQ-amidase, or vice
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versa. The overall process of degradation is likely due to the entire protein structure, but our
results propose modifications to the classical pathway. Full-length wild-type RGS2 has a
glutamine (Q) at amino acid position 2. Glutamine, according to the current formulation of the
N-end rule pathway, is a tertiary destabilizing residue which must undergo deamidation to
glutamic acid (E), arginylation to add a destabilizing arginine, and then recognition by Nrecognins (E3’s) and eventually degradation. Our results, as well as previous results17, show
full-length wild-type RGS2 to have a half-life of approximately 17.5 minutes. On the other
hand, we found tM16 RGS2 to have a half-life of approximately 34.5 minutes, yet it contains
a secondary destabilizing residue (aspartic acid, D) at amino acid position 2. Considering tM16
RGS2 has one less step than full-length wild-type RGS2 in the degradation pathway, it is
realistic to assume that this form of RGS2 would be degraded more rapidly. To complicate
things further, tM5 RGS2, which had an immeasurably short half-life in our hands (<5 min),
and tM33 RGS2, which had a comparable half-life to the full-length RGS2 (17.3 min), both
have primary destabilizing residues at amino acid position 2, phenylalanine (F) and lysine (K),
respectively, yet different half-lives. This could indicate that there is a difference between Type
1 and Type 2 primary destabilizing residues of the N-end rule pathway. However, it is evident
that the number of steps in the degradation pathway need not be proportional to the degradation
rate.

Another potential contributor to the altered half-lives are the amino acid sequences further
downstream of the initiator methionine. The N-end rule emphasizes the role of the second
amino acid, however, the RGS2 G23D mutation has a substantial effect on the protein’s halflife and moreover cellular levels are not affected by MG132 treatment, implying a lack of
proteasomal degradation. Therefore, it is reasonable to assume that amino acids further
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downstream of the initiation site can strongly influence proteasomal degradation. It is
interesting to note that the full-length wild-type RGS2 and tM5 RGS2 only have a four amino
acid difference yet such a large variability in half-lives. This could be in consequence of tM5
RGS2 having two primary destabilizing residues in a row (phenylalanine and leucine) whereas
full-length RGS2 only has a tertiary destabilizing residue (glutamine) followed by a residue
not associated with the N-end rule (serine), otherwise referred to as a stabilizing residue.
Ultimately, our results indicate that the N-end rule is not a perfectly formulated pathway and
even minor changes in the N-terminus of a protein can affect how rapidly it is degraded.

4.4 RGS2 MUTATIONS AS TARGETED GENE THERAPY

A common problem with hypertension and hypertrophic hearts, at least in animal models, is
the expression and function of RGS2 is markedly decreased, which is accompanied with
exacerbated Gαq/11 signaling18. Previous research has shown RGS2 as an intrinsic suppressor
of hypertension and cardiac hypertrophy18,19. Therefore, if the expression of RGS2 could be
restored or if the GAP activity of RGS2 were to be increased, this could represent a promising
direction in treating particular cardiovascular diseases such as hypertension18. An interesting
new area of drug treatment is personalized medicine or gene therapy. Gene therapy is the
therapeutic delivery of nucleic acid polymers via vectors into a patient’s cells to treat disease
by interfering with protein expression or possibly altering genetic mutations 20. There is a lot
of controversy and there are many unknowns about using gene therapy as a treatment for
diseases, most notably cancer20. However, if gene therapy can alter genetic mutations, it would
not be a stretch to assume we could alter wild-type genes to mutant forms. For instance, since
RGS2 is markedly decreased in hypertensive patients, introducing the RGS2 G23D mutant into
the cardiovascular system of a patient might allow for a functional form of RGS2 to be
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produced while also attenuating Gαq/11 to a greater degree than wild-type RGS2. Alternatively,
phenotypes associated with low Gα protein activity, such as platelet Gαs hypofunction3 or
enhanced accumulation of glycogen and heat resistance21, may benefit from introducing the
RGS2 M5V mutation into the genome as opposed to the wild-type form. Undoubtedly, these
are hypothetical treatment options. Nevertheless, altering a protein may limit adverse effects
of commonly prescribed medications like angiotensin II receptor antagonists, as you are simply
varying the amount of Gα signaling instead of completely impeding the action of a receptor. If
these hypotheses are to be tested, the molecular mechanisms regulating RGS2 must first be
uncovered. Our results provide evidence that RGS2 mutations can modify that rate of Gα
signaling, hence it is important to know how a mutation effects the action of a protein before
attempting to target it for therapeutic means.

4.5 RGS2 INITIATION VARIANTS

ATF4 is an example of a gene with multiple initiation sites, however, these initiator
methionines are important for the action of the protein. Under basal, non-stressed conditions,
two upstream open reading frames are translated which results in the exclusion of functional
ATF4 due to an out of frame shift22. However, under stressful conditions (where initiation is
delayed), the ribosome bypasses the upstream open reading frames and initiates translation at
the ATF4 open reading frame. Therefore, ATF4 is increased in response to stress and can
proceed to act as a transcription factor and attempt to mitigate the stressful event on the cell22.
In contrast to ATF4, RGS2 has four initiator methionines1 yet there is little or no understanding
of why these alternative initiation variants, which appear to be conserved among multiple
species, would need to exist. RGS2 does contain multiple domains including a GAP domain
and a plasma membrane association domain1, however both are downstream of each initiator
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methionine suggesting all the RGS2 variants encompass both domains. It has been suggested
that RGS2 has an adenylyl cyclase inhibitory domain between residues 9-111,3. It has also been
proposed that upon Gαs-coupled receptor activation, the longest isoform of RGS2 is
preferentially translated in order produce an RGS2 isoform with the adenylyl cyclase inhibitory
domain1. The concern with this hypothesis is it remains controversial if RGS2 in fact binds
adenylyl cyclase, Gαs, or both, during its inhibitory effect on this signaling pathway. Previous
research shows that RGS2 protein can be immunoprecipitated with purified or cellular Gαs23,24.
If RGS2 is able to impede Gαs signaling without binding to adenylyl cyclase, in other words,
with the remaining residues downstream of methionine 33, the adenylyl cyclase inhibitory
domain would appear to be a redundant mechanism. Another hypothesis for the four initiator
methionines is that certain isoforms may be produced in times of stress. For instance, RGS2 is
known to be able to arrest de novo protein synthesis during times of cellular stress25. As with
other proteins that play a role in the stress response, downstream open reading frames of RGS2
(i.e., tM16 RGS2 and tM33 RGS2) may be more likely to be utilized by the ribosomal
machinery during cellular stress. In the case of tM16 RGS2, this would result in a protein with
a longer half-life. Again, this is simply a hypothesis and there still remains no convincing
evidence for the need of the four initiator methionines.

Our results are consistent with the finding of another group, wherein under basal conditions,
tM16 RGS2 was determined to be the most highly expressed initiation variant in cells
transfected with the full RGS2 mRNA sequence (i.e., lacking any Kozak sequence)1. However
in that study, RGS2 degradation was not considered and the present results suggest that slower
degradation of tM16 RGS2 could also have contributed to its greater abundance. We
hypothesize that this may be due to energy conservation. Simply by looking at the half-lives

92

of the RGS2 initiation variants we can see that RGS2 is a rapidly turned over protein. When
there is limited GPCR activation, there is minimal need for RGS proteins. Therefore, it would
be energy efficient for the cell to produce a shorter isoform of RGS2 and an isoform that was
more stable. tM16 RGS2 maintains the ability to traffic RGS2 to the plasma membrane upon
receptor stimulation1 and is still able to attenuate Gαq/11 signaling. The flaw with this
hypothesis is tM33 RGS2 also maintains the ability to traffic RGS2 to the plasma membrane1
and can attenuate Gαq/11 signaling, but does not have as long of a half-life as tM16 RGS2.
There may be a domain between M16 and M33 that remains critical to RGS2 that causes a
preference of tM16 to be translated. Obviously, these concepts have not been tested and we
cannot say for sure why tM16 RGS2 is preferentially translated as opposed to other RGS2
initiation variants.

4.6 FUTURE DIRECTIONS

Our research has revealed that variations in the N-terminus of RGS2 can affect both the
stability of the protein and its inhibitory activity. Nonetheless, there remain mechanisms that
need to be elucidated about RGS2 regulation and the activity of naturally occurring RGS2
variants. RGS2 is known to attenuate Gαs signaling24 however, our research only focused on
Gαq/11-mediated signaling. Therefore, it would be prudent to perform cAMP experiments that
will help determine the ability of RGS2 isoforms to inhibit Gαs signaling. Such experiments
will help clarify multiple mechanisms including if the degradation rate of an RGS2 protein is
proportional to the ability to attenuate Gαs signaling, and in the process would also likely
determine if the putative adenylyl cyclase binding domain is actually necessary for this
inhibitory function. There is some evidence supporting the presence of an adenylyl cyclase
binding domain between residues 9-11 of RGS2. Thus, if tM16 RGS2 and tM33 RGS2 are
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unable to reduce Gαs signaling, this would suggest the domain is essential. However, if both
shorter isoforms of RGS2 are able to attenuate Gαs signaling, there are several possible
explanations. First, an additional adenylyl cyclase binding domain may exist downstream of
methionine 33. Second, RGS2 is able to bind to and inhibit both adenylyl cyclase and Gαs24.
Third, the RGS domain of RGS2 can bind and inhibit both Gαq/11 and Gαs. All these hypotheses
are testable to determine which, if any, are correct. These experiments may also help strengthen
the claim that the G23D mutation in RGS2 causes a relative preference for the use of the
translation initiation sites at positions 1 and 5 compared to the wild-type sequence3. This would
only become important if it was determined that the putative adenylyl cyclase binding domain
of RGS2 does exist.

Further knowledge on the translational mechanisms of RGS2 could also be obtained in order
to determine if one isoform of RGS2, i.e., tM16 RGS2, is translated preferentially over another
isoform, i.e., tM5 RGS2, or if the difference we see if simply due to different rates of
degradation. If a particular isoform of RGS2 is upregulated during times of stress, a simple
experiment would be to stress cells known to contain wild-type RGS2, perform an immunoblot
and compare stressed RGS2 initiation variants to a non-stressed control group. Since RGS2 is
upregulated during times of stress25, total RGS2 should increase. However, if a particular
isoform increases relatively to total RGS2, it can be assumed that this initiation variant is
preferentially translated times of stress. Ideally, these experiments would be executed using
primary cells in order to determine if this translational effect happens in vivo.

Finally, to strengthen the argument that RGS2 is rapidly degraded via the ubiquitin proteasome
pathway,

two

sets

of

experiments

must

be

performed.

First,

RGS2-ubiquitin

immunoprecipitation experiments should be done to ensure RGS2 is being ubiquitinated.
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Previous research shows wild-type RGS2 to be ubiquitinated26 but this experiment needs to be
repeated for the other RGS2 variants. Second, cells transfected with RGS2 constructs should
be treated with other inhibitors of both the ubiquitin-proteasome pathway and the lysosomal
pathway. This should confirm that RGS2 is degraded via the ubiquitin-proteasome pathway
and may help determine how RGS2 G23D is degraded. If RGS2 G23D cellular levels increase
in the presence of a lysosomal inhibitor, it would suggest that certain RGS2 mutations may be
regulated differently than wild-type RGS2.

4.7 CONCLUSION

Our results provide evidence for the importance of the N-terminus of RGS2 in regards to both
stability and activity of the protein. Any variation within the N-terminus can affect how rapidly
RGS2 is degraded and the ability of the protein to attenuate Gα protein signaling. RGS2 is an
extremely important protein and varying its ability to function can lead to pathophysiological
consequences, as indicated by the RGS2 G23D mutation3. Therefore, we have shown that
naturally occurring N-terminal variants of RGS2 affect stability and activity in vitro.

95

4.8 REFERENCES

1.

Gu S, Anton A, Salim S, Blumer KJ, Dessauer CW, Heximer SP. Alternative translation
initiation of human regulators of G-protein signaling-2 yields a set of functionally
distinct proteins. Mol Pharmacol. 2008;73:1-11.

2.

Yang J, Kamide K, Kokubo Y, et al. Genetic variations of regulator of G-protein
signaling 2 in hypertensive patients and in the general population. J Hypertens.
2005;23:1497-1505.

3.

Noé L, Di Michele M, Giets E, et al. Platelet Gs hypofunction and abnormal morphology
resulting from a heterozygous RGS2 mutation. J Thromb Haemost. 2010;8:1594-1603.

4.

Tang X, Wang Y, Li D, Luo J, Liu M. Orphan G protein-coupled receptors (GPCRs):
biological functions and potential drug targets. Acta Pharmacol Sin. 2012;33:363-371.

5.

Semplicini A, Lenzini L, Sartori M, et al. Reduced expression of regulator of G-protein
signaling 2 (RGS2) in hypertensive patients increases calcium mobilization and ERK1/2
phosphorylation induced by angiotensin II. J Hypertens. 2006;24(Ang II):1115-1124.

6.

Hauger R, Risbrough V, Oakley R, Olivares-Reyes J, Dautzenberg F. Role of CRF
receptor signaling in stress vulnerability, anxiety, and depression. Ann N Y Acad Sci.
2009;1179:120-143.

7.

Lania AG, Mantovani G, Spada A. Mechanisms of disease: Mutations of G proteins and
G-protein-coupled receptors in endocrine diseases. Nat Clin Pract Endocrinol Metab.
2006;2(12):681-693.

8.

Oldham WM, Hamm HE. Structural basis of function in heterotrimeric G proteins. Q
Rev Biophys. 2006;39(2):117-166.

9.

Bansal G, Druey KM, Xie Z. R4 RGS proteins: Regulation of G-protein signaling and
beyond. Pharmacol Ther. 2007;116(3):473-495.

10.

Lee MJ, Tasaki T, Moroi K, et al. RGS4 and RGS5 are in vivo substrates of the N-end
rule pathway. Proc Natl Acad Sci U S A. 2005;102:15030-15035.

11.

Bodenstein J, Sunahara RK, Neubig RR. N-terminal residues control proteasomal
degradation of RGS2, RGS4, and RGS5 in human embryonic kidney 293 cells. Mol
Pharmacol. 2007;71(4):1040-1050.

12.

Kehrl JH, Sinnarajah S. RGS2: A multifunctional regulator of G-protein signaling. Int
J Biochem Cell Biol. 2002;34(5):432-438.

96

13.

Park-Windhol C, Zhang P, Zhu M, et al. Gq/11-mediated signaling and hypertrophy in
mice with cardiac-specific transgenic expression of regulator of G-protein signaling 2.
PLoS One. 2012;7(7):1-11.

14.

Calò LA, Pagnin E, Ceolotto G, et al. Silencing regulator of G protein signaling-2 (RGS2) increases angiotensin II signaling: insights into hypertension from findings in
Bartter’s/Gitelman's syndromes. J Hypertens. 2008;26(5):938-945.

15.

Li N-F, Zhang J-H, Yang J, et al. Association of genetic variations of regulator of Gprotein signaling 2 with hypertension in the general Xinjiang Kazakh population. Clin
Exp Hypertens. 2010;32(5):256-261.

16.

Davydov I V., Varshavsky A. RGS4 is arginylated and degraded by the N-end rule
pathway in vitro. J Biol Chem. 2000;275(30):22931-22941.

17.

Sjögren B, Parra S, Heath LJ, Atkins KB, Xie Z-J, Neubig RR. Cardiotonic steroids
stabilize regulator of G protein signaling 2 protein levels. Mol Pharmacol.
2012;82(3):500-509.

18.

S. Tsang, A. Woo, W. Zhu RX. Deregulation of RGS2 in cardiovascular diseases. Front
Biosci (Schol Ed). 2010;2(6):547-557.

19.

Calò LA., Pagnin E, Davls PA., et al. Increased expression of regulator of G protein
signaling-2 (RGS-2) in Bartter’s/Gitelman's sydrome. A role in the control of vascular
tone and implication for hypertension. J Clin Endocrinol Metab. 2004;89:4153-4157.

20.

Gisbert JP, Chaparro M, Esteve M. Review article: prevention and management of
hepatitis B and C infection in patients with inflammatory bowel disease. Aliment
Pharmacol Ther. 2011;33(6):619-633.

21.

Versele M, De Winde JH, Thevelein JM. A novel regulator of G protein signalling in
yeast, Rgs2, downregulates glucose-activation of the cAMP pathway through direct
inhibition of Gpa2. EMBO J. 1999;18(20):5577-5591.

22.

Ameri K, Harris A. ATF4 (activating transcription factor 4 (tax-responsive enhancer
element B67)). Atlas Genet Cytogenet Oncol Haematol. 2011;14(8):739-743.

23.

Tseng CC, Zhang XY. Role of regulator of G protein signaling in desensitization of the
glucose-dependent insulinotropic peptide receptor. Endocrinology. 1998;139(11):44704475.

24.

Roy AA, Baragli A, Bernstein LS, Hepler JR, Hébert TE, Chidiac P. RGS2 interacts
with Gs and adenylyl cyclase in living cells. Cell Signal. 2006;18:336-348.

25.

Nguyen CH, Zhao P, Sobiesiak AJ, Chidiac P. RGS2 is a component of the cellular
stress response. Biochem Biophys Res Commun. 2012;426(1):129-134.

97

26.

Sjögren B, Swaney S, Neubig RR. FBXO44-Mediated Degradation of RGS2 Protein
Uniquely Depends on a Cullin 4B/DDB1 Complex. PLoS One. 2015;10(5):e0123581.

98

Chapter 5: Appendices
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1

APPENDICES

5.1

RGS2-LUCIFERASE PROTEIN DEGRADATION

Originally, we wanted to take advantage of RGS2-luciferase fusion constructs to measure
RGS2 stability and variability translation. The C-terminus of RGS2 constructs were fused with
a renilla luciferase protein which, in theory, would emit light when RGS2 was synthesized.
Thus, an increase in luminescence would be indicative of higher RGS2 levels. Unfortunately,
luciferase has multiple initiator methionine residues which were preferentially chosen to
initiate synthesis when mutations were introduced into the RGS2 protein. As seen in Figure
5.1, the majority luminescence we were detecting was simply luciferase itself, not fused with
RGS2.
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RGS2 construct

Rluc WT M1

M5 M16 M33 1STOP M5L M5V pkM1 pkM5 pkM16 pkM33

50 kDa
36 kDa

Figure 5.1. RGS2-luciferase fusion proteins. RGS2-luciferase fusion constructs were
immunoblotted with anti-renilla luciferase. 50 kDa correlates to RGS2 and luciferase fusion
and 36 kDa correlates to luciferase alone. Constructs include: Rluc = empty renilla luciferase
control plasmid; WT = full-length wild-type RGS2; M1 = methionine 5, 16, and 33 were
mutated to alanine; M5 = methionine 1, 16, and 33 were mutated to alanine; M16 = methionine
1, 5, and 33 were mutated to alanine; M33 = methionine 1, 5, and 16 were mutated to alanine;
1STOP = a stop codon was introduced between methionine 1 and 5 of RGS2; M5L =
methionine 5 was mutated to leucine; M5V = methionine 5 was mutated to valine; pkM1 =
pseudo-Kozak sequence was introduced downstream of methionine 1; pkM5 = pseudo-Kozak
sequence was introduced downstream of methionine 5; pkM16 = pseudo-Kozak sequence was
introduced downstream of methionine 16; pkM33 = pseudo-Kozak sequence was introduced
downstream of methionine 33. Renilla luciferase protein = 36 kDa whereas RGS2-luciferase
fusion protein = 50 kDa.
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